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ABSTRACT PAGE
Pax5 is an alternatively spliced transcription factor that regulates B cell development,
activation, and differentiation. Although misexpression of Pax5 is associated with
malignancies such as lymphomas, research has yet to elucidate the function of specific
Pax5 isoforms and to further correlate these isoforms with disease or B cell developmental
stages. Our study hypothesized that in the anterior kidney, blood, and spleen of rainbow
trout, specific Pax5 isoforms characterize individual B cell populations as a means of
modulating Pax5 activity. Using flow cytometric analyses with antibodies recognizing the
Pax5 paired domain, exon 6 domain, and C-terminus, we demonstrate that B cell
populations differentially express Pax5 isoforms. Additionally, using the developmental
markers Xbp1-S, EBF, and HCmu, we reveal that Pax5 isoforms lacking a paired domain
are present at the earliest stages of B cell development. Furthermore, we discover for the
first time in trout that these early developing B cell populations exist in the secondary
immune tissues, blood and spleen. With these findings, we propose a model in which the
stages of B cell development and activation are delineated by combinations of Pax5
domain expression which we have termed the "Pax5 signature". The identification of Pax5
signatures with flow cytometry provides a means to assess aberrant molecular expression
in B cell populations and has important implications for clinical diagnostics.
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Chapter 1. Introduction
The immune system is comprised o f a multitude o f cells capable of targeting
foreign pathogens and altered self-cells such as cancer cells [1]. Innate immunity
functions in both vertebrates and invertebrates to activate inflammatory responses leading
to pathogen destruction [1]. In contrast, the acquired immune system is highly specific
and found only in vertebrates. When activated, it operates in conjunction with the innate
immune system by employing T lymphocytes, B lymphocytes and natural killer cells.
The B lymphocyte, the focus o f this study, is the antibody secreting cell o f the humoral
(antibody) response. Through a highly regulated process dependent on transcription
factor cascades and the microenvironment, B cell progenitors develop into mature B cells
that express membrane immunoglobulin (IgM). Upon antigen encounter, mature B cells
activate and differentiate into Ig-secreting plasma cells, which secrete antibody that binds
antigen with high specificity [1].
The phenotypic pathway o f B cell development and activation is well delineated
and fairly conserved across vertebrates. However, unique evolutionary differences in the
molecular mechanisms and immune tissue locations o f B cell development exist between
higher and lower vertebrates. While mammalian B lymphopoiesis occurs in the bone
marrow, lymphopoiesis in lower vertebrates occurs in alternative primary immune
tissues. O f particular interest are the teleosts which lack bone marrow but instead
maintain lymphopoiesis in the anterior kidney and launch an acquired immune response
comparable to that o f their mammalian counterparts [2-4]. The importance o f both

1

similarities and differences between these two groups will be emphasized and explored
throughout this chapter.
In addition to cross-species comparisons, the molecular mechanisms determining
B cell differentiation, particularly the B cell specific factors, require further examination.
The master regulator o f B cell development is the paired domain transcription factor Pax5
[5-7]. Pax5 is translated from an alternatively spliced mRNA transcript and is necessary
for the maintenance of the B cell phenotype [8, 9]. While the role o f Pax5 in B cell
development is conserved, researchers have yet to elucidate the function and expression
of multiple Pax5 isoforms across immune tissues and species. Identifying the roles of
individual Pax5 isoforms in B cell development may have important clinical implications,
as the misexpression of Pax5 isoforms correlates with erroneous B cell proliferation and
malignancy [10-12]. This chapter will present the current paradigms in B cell
development and Pax5 alternative splicing, and will highlight important unanswered
questions linking these mechanisms.

1. B Cell Development
B cell development is a highly regulated, sequential process dependent on the
microenvironment. Transcription factors, which are DNA-binding proteins, function to
both activate genes guiding B lymphopoiesis and to suppress genes driving alternative
cell fates. Cytokines and their receptors also enrich the microenvironment o f primary and
secondary immune tissues and promote the acquisition o f B cell competency (the ability
o f a cell to follow a particular cell lineage). In fact, each stage o f B cell development
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(Figure 1.1) is defined by distinct expression patterns o f molecular markers, including
transcription factors (reviewed in [13]), cytokine receptors, and Ig heavy (H) and light
(L) chain gene rearrangements. As B cell progenitors progress through the developmental
stages marked by these molecular patterns, they gradually lose their alternative lineage
potential until finally acquiring a mature B cell phenotype.

1.1 Hematopoiesis and Common Lymphocyte Progenitors (CLPs)
Hematopoiesis is the process by which pluripotent hematopoietic stem cells either
self-renew or acquire a progenitor fate capable o f producing all immune cell types. In
most vertebrates, hematopoietic tissues arise from the ventral mesoderm during fetal
development [14]. During fetal development, the spleen functions as the primary
hematopoietic site. At birth, mammalian hematopoiesis primarily occurs in the bone
marrow and continues there throughout adulthood. While bone marrow serves as the
primary immune tissue in mammals, other tissues, such as dorsal aorta and anterior
kidney, serve as a site for hematopoiesis in lower vertebrates such as amphibians,
chickens and teleosts (reviewed in [15]).
The rainbow trout anterior kidney (defined in [2, 16]) functions as the primary
immune organ and site o f hematopoiesis.. These findings were primarily confirmed by
antigen inhibition assays in which anterior kidney cells had reduced antigen recognition
capabilities when compared to spleen cells. The results agreed with findings observed in
murine bone marrow and spleen [4]. In a further parallel, both the anterior kidney o f
teleosts and the bone marrow of mammals house the adventitial, endothelial, and reticular
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cells [17]. The anterior kidney also contains progenitor cells characterized by conserved
early molecular markers, such as early B cell factor (EBF), recombination activating gene
(RAG)-1,-2, and Ikaros [18-20]. Although murine and human hematopoietic cells are
typically identified and defined by the antigenic surface marker CD34 (previously My10), an equivalent cell surface marker for trout hematopoietic cells has yet to be
identified [21, 22].
In all vertebrates, the pluripotent progenitor cells produced by hematopoiesis have the
potential to differentiate into all blood cell lineages, but they are developmentally
restricted to specific lineages by the expression o f hormones and cytokines in the stroma
o f hematopoietic tissues. Erythropoietin, for example, restricts cells to erythrocyte fates
while cytokines interleukin (IL)- 15 and IL-6 restrict cells to natural killer (NK) cell and
granulocyte lineages respectively (reviewed in [23]). The lymphoid lineage, particularly
B-lymphocytes, requires exposure to IL-7 [24, 25]. Cells driven toward NK, T- and Blymphocyte fates are collectively known as the common lymphocyte progenitors (CLP).
Common lymphocyte progenitors biased towards the B cell fate are characterized
by expression o f the transcription factors Ikaros and EBF [13, 18, 26]. Ikaros expression
occurs prior to the activation of B cell-specific genes and is required for lymphoid fate in
both teleosts and mammals [18, 27]. Mice homozygous deficient for Ikaros lack NK, T-,
and B-lymphocytes, a finding that demonstrates Ikaros is necessary as a lymphoid
progenitor regulator [18, 28]. Similar to knock-down experiments for Ikaros, knockdown
o f EBF results in reduction of lymphoid fates and an increase in myeloid-derived fates.
Additionally, ectopic expression of EBF directs pluripotent stem cells towards B cell
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fates [29]. While Ikaros functions as a CLP regulator, EBF has a more specific role in B
cell commitment as it regulates, and is regulated by, Pax5 [29] later in development.
Common lymphocyte progenitors are additionally defined by their level o f Ig
gene rearrangements. RAG1 locus activation occurs in early multipotent progenitor cells
prior to B cell gene expression [30]. Concurrently, these CLP cells begin expression of
terminal deoxyncleotidyl transferase (TdT) which is necessary for antigen receptor
diversity [30, 31]. Prior to differentiation to non-lymphoid fates, CLPs begin to produce
more D h-J h (diversity and joining gene segments) rearrangements [23], but are not
necessarily committed to the B cell fate [30].
Recently, populations o f early developing B cells including common lymphocyte
progenitors have been compared using trout and murine primary immune tissues. Using
flow cytometric analysis and antigenic markers o f RAG1 and EBF, Zwollo et al. [32]
demonstrated that similar early B cell populations exist in both murine bone marrow and
trout anterior kidney. In addition to expressing these early progenitor cell molecular
markers, these cell populations were o f similar large size (i.e. high in forward light
scatter- FSC), further emphasizing the evolutionary parallels in mammals and teleosts.

1.2 Pro-B -M ature B Cell Development
As with CLPs, the more differentiated stages o f B cell development (Figure 1.1)
may be identified by molecular changes in cell surface markers, transcription factors, and
Ig rearrangements. Pro-B cells differ from CLPs since they are restricted to the B cell fate
and can no longer produce T cells. In addition, murine pro-B cells are defined by cell
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surface markers B220 and CD43 [33-35]. Both murine and teleost pro-B cells are marked
by continued expression o f EBF and RAG1 with the new expression o f Pax5 [32], Pax5
is the master regulator o f B cell commitment and development; Pax5-/- cells arrest at the
pro-B stage [7, 36], Murine and teleost pro-B cells are also characterized by
rearrangement o f the DJ gene segments at both IgH loci [37, 38].
After the initial heavy chain rearrangement in pro-B cells, cells enter the pre-B
stages o f development. The pre-B stages are divided into two phases: pre-BI and pre-BII
(includes large pre-BII and small pre-BII). During pre-BI, EBF and mammalian CD43
expression decline and the primary immune cells begin expressing heavy chain (HC) mu
[32, 39-41]. Assembly o f the pre-B cell antigen receptor (preBCR) begins as the
surrogate light chain (LC) forms from the Iga/IgP subunits [23, 36, 38, 42]. Cells then
undergo positive selection for the preBCR and progress to the pre-BII stage.
In the pre-BII stage, pre-BII cells no longer express either EBF or RAG1 [32].
The variable (V) gene segment recombines to the DJ gene segment and the locus
undergoes VDJ chain rearrangements [37]. During this stage, cells become smaller,
shifting from the larger pre-BII cell morphology to smaller pre-BII cell morphology, as
evidenced through the FSC o f flow cytometric analyses [32]. Remarkably, the relative
frequency o f the small, late developing B cell populations (including small pre-BII,
immature and mature B cells) is well conserved between mouse bone marrow cells and
trout anterior kidney cells; approximately 1% o f bone marrow and anterior kidney cells
are in the late developing stages.
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The end o f pre-BII development and beginning o f the immature B phase is
characterized by LC gene rearrangement [37]. The immature B cell is the first o f the B
cell lineage to express surface IgM (reviewed in [43]). In mice, immature B cells will
migrate from the bone marrow to the surrounding lymph nodes, upregulating mature B
cell genes as they travel [44]. In teleosts such as trout, research suggests migration occurs
from anterior kidney to either the posterior kidney or the spleen [2]. Once inside the
secondary immune tissues, B cells will mature, continue to express functional membrane
bound IgM, and remain in a resting state until antigen activation.

2. B Cell Activation- Plasmablasts, Plasma Cells, and Memory Cells
Upon antigen activation, B cells will terminally differentiate into one o f three
fates: short-lived plasma cell, long-lived plasma cell, or memory B cell. Similar to early
B cell development, this process follows a regulated sequence o f events, beginning with
plasmablast proliferation. During terminal differentiation, B cells will either remain in
their final secondary immune tissue location or return to the primary immune tissue
where they can survive within supportive niches as long-lived plasma cells. As observed
in earlier stages o f B cell development, the process o f terminal differentiation and plasma
cell survival is highly dependent on both transcription factor expression and the
microenvironment.
In the secondary immune tissues, mature resting B cells encounter antigen,
activate, and then begin proliferating as antibody secreting plasmablasts. Plasmablasts are
primarily found in the spleen or in the blood stream migrating to other tissues. In both
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mammals and teleosts, proliferating plasmablasts are also present in bone marrow
(anterior kidney for teleosts), spleen, and blood [16]. The peripheral blood o f teleosts
contains plasmablasts but lacks plasma cells, as exemplified by the lack o f cell antibody
secretion in the presence o f the cell cycle inhibitor, hydroxyurea (reviewed in [45]) [3].
However, plasmablasts isolated from peripheral blood are incapable o f differentiating to
mature plasma cells in vitro [16], emphasizing the importance o f microenvironmental
factors such as the presence o f cytokines, on B cell terminal differentiation [3]. It is not
known whether peripheral blood B cell terminal differentiation occurs in vivo.
One key developmental marker o f proliferating and differentiating B cells is the
X-box binding protein, X bpl. X bpl is a key regulator o f the unfolded protein response
and its expression allows antibody-secreting cells to accumulate proteins in the
endoplasmic reticulum without triggering the unfolded protein response [46-48]. During
mammalian and teleost plasmablast proliferation, Pax5 is downregulated, thus reversing
the Pax-5 mediated inhibition o f Xbpl [49]. X bpl upregulation facilitates the production
o f IgM [48], the isotype o f naive B cells. Flow cytometric analyses have utilized
combinations o f antigenic markers o f X bpl-S (the stable form o f protein induced by
antigenic stimulation), HCmu (the heavy chain o f IgM), and Pax5 to distinguish
subpopulations o f differentiating plasma cells in both trout and mouse by their distinct
expression patterns [16]. When compared to mouse cells, trout cells do not produce as
high a frequency of activated B cells when cultured in LPS (see [50] for use), however
both trout and mouse plasmablasts exhibit intermediate levels o f Xbp and HCmu as Pax5
levels decrease. As plasmablasts differentiate to plasma cells, they express very high
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levels o f X bpl and HCmu and no longer express Pax5. Thus, the patterns o f Xbpl
expression and other conserved molecular markers provide conclusive evidence that
plasmablasts are a conserved population distinct from plasma cells.
A plasm ablast’s differentiation into a short-lived plasma cell is accompanied by
important changes in IgM expression. Plasma cells are antibody-secreting cells that
downregulate membrane IgM and they therefore no longer bind antigen. Instead,
mammalian plasma cells upregulate and secrete Ig o f various isotypes including IgM
(reviewed in [51]). These short-lived plasma cells can be identified by their lack o f
somatic hypermutations; B cells with less specific binding to the antigen will undergo Ig
somatic hypermutations to increase specificity. Teleosts also upregulate secreted forms
o f Ig, but with less isotype switching. Initially, IgM was proposed to be the only secreted
teleost Ig, but recent studies indicate the additional presence o f secreted IgD and IgT [5254]. The lack o f mutational variability within the secreted Ig population is important as it
suggests primary antigen exposure and can be used to distinguish short-lived plasma cells
from long-lived plasma cells and memory cells.
Long-lived plasm a cells (LLPCs) are plasma cells that have been previously
exposed to antigen and thus secrete high affinity antibody [51]. The term “humoral
memory” is applied to LLPCs as they can maintain active antibody secretion for months
to years without re-exposure to antigen. In mice, LLPCs arise from a distinct plasma cell
precursor population in the bone marrow [55]. These precursors differentiate to LLPCs
and are maintained in a bone marrow niche o f specialized stromal cells [51, 55]. Just as
the mouse bone marrow harbors LLPCs, evidence suggests a similar role for the trout AK
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[reviewed in[56], [3, 57]. Upon antigen stimulation, these cells within the anterior kidney
will continue to secrete antibodies weeks beyond those in the blood and spleen [3].
Furthermore, they do not require further antigen stimulation to remain active, Igsecretors. Although not yet reported, it is likely these cells are supported within anterior
kidney niches similar to those within mouse bone marrow [56].
In addition to differentiating into short-lived and long-lived plasma cells,
activated B cells may also acquire a memory cell phenotype. Mammalian memory cells
are distinct from plasma cells in that they continue to express membrane Igs. However,
these memory cells have often undergone both isotype switching and somatic
hypermutation o f their variable gene segments (reviewed in [23]). Mammalian memory
cells are further defined as cells that rapidly increase antibody production upon antigen
re-exposure and produce higher affinity antibodies than those generated during the
primary immune response. The teleost immune system also exemplifies memory
responses as production o f a secondary immune response in trout immune cells increases
antibody secreting cells without altering the number o f antigen-sensitive clones.
However, unlike mammalian memory cells, teleost memory cells do not appear to exhibit
affinity maturation (the production o f antibodies with higher antigen affinity) [23, 58].
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3. The Role o f Pax5 in B Cell Commitment
The transcription factor Pax5 is considered to be a key regulator o f B cell lineage
commitment and is additionally expressed in both the developing central nervous system
(CNS) and the adult testis [59]. As a member o f the paired box (Pax) family o f
transcription factors, Pax5 shares a conserved DNA-binding domain o f 128 amino acids
known as the paired domain. Pax5 is necessary in developing B cell populations as it
activates genes involved in B cell receptor formation and represses genes directing
alternative lineage fates [60-63]. Its subsequent downregulation is critical for plasma cell
proliferation and terminal differentiation. Given its crucial role in the early proliferative
stages o f B cell development, it is not surprising that misexpression o f Pax5 leads to
oncogenesis. Additionally, Pax5 is one o f the many genes processed via alternative
splicing, although the role of multiple Pax5 isoforms in B cell development, activation,
and cancer formation remains poorly understood.

3.1 Pax5 and Pax Family
The Pax family consists o f nine transcription factors which express a conserved,
bipartite paired domain and some or all o f two additional motifs (see Figure 1.2 for Pax5)
[64]. X-ray crystallography demonstrates that the two sub-regions o f the paired domain
include an N-terminal PAI domain encoded by exon 2 and a C-terminal RED domain
encoded by exon 3 [65]. These domains bind two half-sites on adjacent DNA major
grooves [66]. The Pax family is further divided into four classes by the presence o f a
conserved homology region called the homeodomain and an octapeptide repeat region
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(reviewed in [67]). Class one, consisting o f Pax 1 and 9, contains the octapeptide region,
but no homeodomain. Class two, consisting o f Pax2, 5, and 8, has the octapeptide region
and a partial homeodomain which lacks the ability to bind DNA. Class three, consisting
of Pax3 and 7, has both the octapeptide region and a full homeodomain. Finally, class
four contains Pax 4 and 6, displaying the full homeodomain and no octapeptide repeat.
Pax5 falls into a transcription factor family with unique homology region
properties and transactivating potential. The partial homeodomain homology region
allows for interaction with the TATA-binding protein at the gene promoter, enabling
Pax5 to directly manipulate gene transcription [68]. This region also contains a binding
m otif for the retinoblastoma gene product which is important in tumor suppression [68,
69]. The Pax5 octapeptide m otif interacts with the Groucho family o f corepressors to
repress gene transcription [70]. The C-terminal domain o f Pax5 contains a 55 amino acid
transactivating domain which is serine/threonine/proline-rich. The transactivating domain
is negatively regulated by inhibitory sequences in the extreme C-terminus [71].
In addition to their homology regions, Pax family members share commonalities
in their conservation across species, alternative splicing patterns [9, 72-74] and oncogenic
properties [67]. Pax genes are shared amongst mammals and lower vertebrates such as
zebrafish, Xenopus, trout, and amphioxus [71, 72, 75-77]. Alternative splicing (reviewed
later in this chapter) has been identified for each o f the classes with the majority of
isoforms containing an exon 2 deletion (for review, see [72]), resulting in a non
functional paired domain.
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3.2 Pax5 in B Cell Development and Activation
Functional studies o f Pax5 using knockout and targeted mutation approaches
demonstrate its role in B cell development and activation. Immune cells o f mutant mice
homozygous for Pax5 deletions are unable to proceed past the pro-B developmental stage
[7]. These cells are capable o f undergoing D-J rearrangements at the HC locus, but
express significantly reduced V-D-J rearrangements (reviewed in [78]) [5]. Arrested proB cells are not restricted to the B cell lineage: culturing these cells in the presence o f
lineage-specific cytokines allows redirection o f cell fate. Furthermore, Pax5 re
expression via viral induction is sufficient to reverse the pro-B arrest and completion o f B
cell differentiation [6].
Pax5 alters B cell development through a mechanism o f gene activation and
repression [63]. Delogu et al. [61] identified 110 genes repressed by Pax5, and
demonstrated that continuous Pax5 mediated repression o f alternative lymphoid and
myeloid genes was required to maintain the B cell lineage. It is therefore unsurprising
that release of Pax5 repression is necessary for terminal plasma cell differentiation. In
addition to genes related to cell adhesion and cellular migration, Pax5 also represses
genes involved in isotype expression. Specifically, murine Pax5 binds and represses the
enhancer of HC 3 a, as demonstrated via transient transfection studies o f pro-B, pre-B and
mature B cell lines [79, 80]. Pax5 also suppresses transcription o f the Ig J chain gene, a
process which must be reversed before cytokines such as interleukin-2 [81 ] and the
transcriptional repressor Blim p-1 [82] can induce terminal plasma cell differentiation.
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More recently, Schebesta et al. [60] used microarray technology to identify 170
Pax5-activated genes in murine pro-B cells, half of which are subsequently
downregulated in plasma cells (reviewed in [83]). One o f the potential mechanisms o f
Pax5 gene activation is histone modification, as evidenced by ChlP-on-chip studies [60].
These studies define active histones by the patterns o f histone lysine methylation and
acetylation (i.e. H3K4me2, H3K4me3, and H3K9ac). Microarray studies demonstrate the
necessity of the Pax5 DNA binding domain for these active histone marks: upon Cremediated conditional knockout o f the Pax5 DNA binding domain, pro-B cells exhibit
fewer active histone marks than pro-B cells with intact versions o f wildtype Pax5 [83].
Recent studies have further demonstrated that Pax5 induces changes in histone activation
by recruiting chromatin remodeling and histone modifying complexes [62]. Pax5 is also
necessary to activate genes involved in cell cycle regulation and metabolism [60],
suggesting the expansive role o f the transcription factor in developmental processes.

3.3 Pax5 Alternative Splicing
Alternative splicing is a mechanism by which the exons o f an RNA transcript are
differentially combined to produce different functional protein products. By recombining
RNA exons in multiple ways, alternative splicing enables an economical means by which
a single gene can encode multiple protein isoforms. The Pax family is one o f several
transcription factors subjected to this process [9, 72-74]. The first Pax isoforms observed
were those o f Pax8; four alternatively spliced Pax8 mRNA transcripts were identified in
human kidney cells lines via PCR amplification and RNAse protection assays [73].
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Further analysis with transient transfection assays demonstrated that each isoform has
distinct C-terminal transactivating properties. Unique patterns o f Pax8 mRNA transcripts
were also identified in mouse cell lines representing different stages o f embryogenesis,
suggesting the isoforms are carefully regulated during development.
Shortly after researchers identified Pax8 alternative splicing, similar observations
were made for the additional Pax family members, including Pax5. The murine Pax5,
identified in pro-B cell lines, mature B cell lines and spleen cells, has four distinct
isoforms - Pax5a (full length: FL), b, d, and e (see Figure 1.2) [9]. Pax5b and e have
deletions in exon 2, leading to a truncated, non-functional DNA-binding domain. Studies
o f plasma cell lines suggest that low levels o f Pax5b are present in the cell line SP20, one
o f three plasmacytoma lines tested [9]. In contrast, Pax5a is completely down-regulated
in this same cell line. Subsequent functional studies demonstrated that although Pax5e
alone is non-functional, in combination with Pax5a it may increase reporter gene activity
[9, 84].
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Figure 1.2 [9]. Murine Pax5 isoforms shown as cDNA sequence. Numbers represent
nucleotide number. Red box: paired domain (exons 2 and 3); purple: octamer region
(exon 5); yellow: homeodomain homology region (exon 6); green: transactivation domain
(exons 8 and 9); bright red: repressor domain (exons 9 and 10); blue: novel C-terminus.
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Similar to Pax8, murine Pax5 isoforms d and e have alternatively spliced Ctermini, creating novel C-termini and deleted homeodomains. The novel C-terminal
region contains significantly fewer Ser/Thr/Pro residues than Pax5a, altering its
transactivating potential [9]. Functional studies o f Pax5d reveal that the isoform binds
DNA with the same affinity as Pax5a and thus acts as an inhibitor o f Pax5a in a dosedependent manner [84]. The inhibitory role o f Pax5d is further emphasized by its
decreased presence in LPS activated cells [84]. As Pax5a is needed for cell proliferation,
it is logical that the inhibitor o f Pax5a would be downregulated during B cell activation.
Interestingly, while the Pax5a DNA-binding affinity is decreased in B lymphocytes o f
aged mice, the Pax5d DNA-binding affinity remains constant, further suggesting a unique
role for Pax5d in B cell processes [85].
Remarkably, similar Pax5 isoforms are observed across species, including but not
limited to humans, mice, fish (see Figure 1.3; Zwollo, unpublished data), and amphioxus
[9, 12, 72]. Flumans [12], trout (Zwollo, unpublished data), and amphioxus [72] have
isoforms that either include or exclude exons 7-9, drastically altering their transactivating
potential. Likewise, conserved deletions o f exon 2 (the DNA-binding domain) in
amphioxus, trout (Zwollo, unpublished data), mouse, and human isoforms [9, 10, 72] are
particularly noteworthy. However, beyond a few functional studies o f isoforms lacking
exon 2, a definitive role for expression o f this isoform has yet to be identified.
Numerous studies have examined the role o f aberrant Pax5 isoform expression in
cancer development. Pax5 is considered a proto-oncogene since its misregulation often
correlates with lymphomas and leukemias [86]. Haploinsufficiencies o f full length Pax5
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correlate with acute lymphoblastic leukemia (ALL; [87]) whereas alternatively spliced
Pax5 variants correlate with cancer formation. Robichaud et al. [12] found that human
lymphoma samples express a reduced number o f Pax5 isoforms, specifically the full
length Pax5 and the Pax558 (lacking exon 8), in comparison to healthy samples which
express multiple isoforms. Additionally, the expression o f a novel Pax5 exon discovered
by Borson et al. [11] is downregulated in patients with multiple myeloma. Despite the
promise in these results, other studies have been unable to identify a single pattern o f
isoform expression that could be used to distinguish normal from malignant B cells [10].
Similarly, researchers have cautioned the testing o f alternative splicing in cancer cells as
unrelated stress factors such as overnight sample shipping may induce increased Pax5
isoform expression [88]. Thus, although multiple splicing patterns have been reported in
malignant cells, further analysis is required to establish any conclusive or diagnostic
correlations.
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Figure 1.3. Trout Pax5 isoforms shown as cDNA sequence (adapted from Zwollo,
unpublished data). Red box: paired domain; purple; octamer region; yellow:
homeodomain homology region; green: transactivating domain; bright red: repressor
domain; T : additional C-terminal amino acids.
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4. Rationale for the Current Study
Although the role o f Pax5 in B cell development and activation has been well
described, the temporal-spatial expression patterns, functions, and consequences of
multiple Pax5 isoforms in these processes remain unknown. Numerous studies emphasize
the importance o f Pax5-regulated gene activation and repression in B-cell development
[60, 61]. Through conditional knockouts targeting Pax5 exon 2, repressor studies reveal
the necessity o f the DNA-binding domain in the activation o f B cell commitment genes
[60]. Additionally, full length Pax5 (Pax5 FL) knockouts reveal the importance o f Pax5
inhibition. Without the transcription factor, cells re-express previously Pax5-inhibited
genes. However, what these studies fail to address is the function o f specific Pax5
isoforms, including Pax562, in gene targeting. Functional studies exploring Pax5
isoforms with paired domain deletions and novel C-termini have indicated a role for these
isoforms in increasing Pax5a gene activation [84]. Therefore, it is likely these isoforms
contribute to B cell developmental processes and mechanisms o f regulation.
Additionally, identifying the function o f these isoforms across species will help
elucidate the evolutionary forces driving immune system development. A cross-species
analysis may also enable researchers to identify the most relevant isoforms in B cell
development and disease. As previously stated, the rainbow trout is an excellent model
organism for cross-species comparisons. Despite lacking bone marrow and lymph nodes,
its immune system functions similarly to that in humans. Furthermore, almost no
published studies have compared B cell development in teleosts versus mammals,
including studies o f Pax5 isoform expression and function.
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The first step in evaluating the functional potential o f Pax5 isoforms is to identify
their existence in individual B cell populations. Previous studies have primarily utilized a
traditional or nested PCR approach requiring RNA from pooled cell samples to identify
novel Pax5 isoforms [9, 72, 89]. While this approach is sufficient to identify the existence
o f Pax5 isoforms, it does little to assess their expression within individual developing,
proliferating, and differentiating B cell populations. The frequency o f cells representing
specific B cell sub-populations is potentially quite small [2, 16, 76]. If individual
isoforms function in these small, transient populations, a PCR approach will be unable to
demonstrate the relative abundance (and potential importance) o f these isoforms
compared to isoforms found in larger B cell populations. Thus, a novel approach utilizing
flow cytometry is necessary to elucidate the expression and potential role o f Pax5
isoforms in B cell development.
Studies have previously employed flow cytometry to establish “B cell signatures”
or cytometric patterns representing the frequency and intensity o f conserved molecular
markers that demarcate B cell populations in different immune tissues [16]. As a
fingerprint identifies an individual, flow cytometric analysis has successfully
distinguished between trout and mouse immune tissues by demonstrating each immune
tissue’s distinct frequency o f developing B cell populations, including CLPs, pro-B, preB, mature B, proliferating, and plasma cells [2, 32, 76]. Furthermore, lymphocyte cells
stained with antibodies against the Pax5 paired domain and analyzed by flow cytometry
demonstrate the patterns o f paired domain expression in B cell populations previously
delineated in the literature. Therefore, flow cytometry provides a reliable and
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reproducible means o f characterizing both B cell populations and whole immune tissues.
Therefore, the aim o f the current study was to use flow cytometry to evaluate patterns o f
Pax5 isoform expression in developing mouse and trout B cell populations and to
characterize the “Pax5 signatures” o f mouse and trout immune tissues.

5. Flow Cytometric Analysis
Flow cytometry is a technique used to identify cells by the key molecular markers
o f individual cells comprising a larger population. Cells from tissues are stained with
fluorescent-tagged antibodies and are then run single file through a laser beam, collecting
information on the cell’s fluorescence, its forward light scattering, and its side light
scattering. Each cell passing through the laser is considered an “event” and the
fluorescence and light scattering information for each event is captured in a computer
graphic that can be easily read by the researcher.

5.1 Flow Cytometer Fluids
The simple set up for flow cytometry is diagrammed in Figure 1.4. Cells are
drawn up from a 96-well plate, mixed with sheath fluid (a proprietary buffer saline
solution with detergent), and pushed through a flow chamber via laminar flow. In the
flow chamber, cells are aligned single file by hydrodynamic focusing [90]. After passing
through a laser beam, the cells are discarded into a waste container.
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5.2 Forward Angle Light Scatter (FSC) and Side Angle Light Scatter (SSC)
As cells are excited by a laser, light is scattered based on the size and complexity
(indication of shape due internal cellular components) o f the cell. FSC is light diffracted
from the cell in the direction of the laser beam. Larger cells will have greater FSC than
smaller cells. The FSC light is detected by a lens and translated into electronic pulses by
a photodiode [90]. SSC is light reflected and refracted at 90° and is based on the cell’s
topography (membrane roughness), cytoplasmic granularity, and shape o f organelles.
SSC is only 10% of total light scattering and therefore must be detected by a more
sensitive device such as a photomultiplier tube (PMT), which will amplify the weak
signal.

5.3 Fluorescence
The BD FACS Array Bioanalyzer can detect fluorescence from four regions o f the
light spectrum: infrared (IR), yellow, red, and far red. The emitted sample fluorescence
is directed towards the optical filters using a series o f mirrors and beam splitters. The
filtered light is then amplified with a PMT and converted into electrical signals which can
be read by the computer. If fluorochromes overlap in their emission spectra, BD
FACSArray provides a compensation tool to collect data from fluorochromes only within
a specific wavelength range.
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Figure 1.4. Flow cytometer process. Light blue arrows delineate cell pathway; bright blue
arrows represent laser pathway. Single cell suspensions are mixed with sheath fluid and
cells are passed individually through a laser beam. As cells pass through the beam, light
is scattered and the direction o f the scattering is detected by an optic lens. Additionally,
the laser excites antibody fluorochromes. The light emitted from individual
fluorochromes is passed through optic filters to detectors. The information is then passed
to a computer which presents the intensity o f light scattering and fluorochrome
fluorescence in a graphic image.
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5.4 Data Interpretation
Information from each cell is presented graphically on the computer as it is passed
through the laser. A typical experiment will collect around 30,000 events, a high number
designed to detect even small cell populations, such as plasma cells. During a typical
experiment, multiple graphs will be used at once to examine the size o f the cells versus
the complexity, the size o f the cells versus their fluorescence, expression o f one
fluorochrome-labeled antibody versus a second fluorochome-labeled antibody, and a
histogram for the number of cells expressing a fluorochrome at any given intensity of
fluorescence.
When studying lymphocytes, the lymphocyte population is first gated based on a
graph o f FSC versus SSC. Previous experiments have already identified how lymphocyte
populations should appear on the FSC v. SSC graphs [2]. Figure 1.5 provides an example.
This graph can be examined both in dot plot form (Figure 1.5a), where each cell is
represented as one dot on the graph, or in contour form (figure 1.5b), where populations
o f cells are represented by varying degree o f intensity. Once the lymphocyte cells are
gated, the population o f cells may be examined for their fluorescence intensity o f a
particular antibody (see Figure 1.5c). In the example provided, the cells have been stained
for two antibodies: one in the yellow emission wavelength and one in the red wavelength.
The frequency o f cells in a given population can be identified based on the four criteria
listed above. Thus, flow cytometry provides a valuable means to characterize tissues
composed o f diverse cell populations.
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Figure 1.5. Flow data graphs. Ab = antibody. A) Cells individually recorded as “events”
and separated according to size (FSC) and complexity (SSC). The region o f lymphocytes
is gated as population R l. B) The same population o f lymphocytes is represented in
contour form. C) Four populations o f cells stained for two antibodies are presented. Ab 1
emits light in the yellow wavelength and Ab 2 emits light in the red wavelength. The
populations of interest are boxed. Population R2 has high Ab 1 staining and medium Ab2
staining. R4 has low or no Ab 1 staining and medium Ab 2 staining. R3 is high in Ab 1
staining and high in Ab2 staining. The unboxed region represents a double negative for
Ab 1 and Ab 2 staining.
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6. Hypothesis and Research Aims
Pax5 regulates B cell development through a process o f coordinated gene
activation and repression. Pax5 isoforms are able to enhance and inhibit full length
Pax5’s ability to activate gene expression, thus potentially altering the course o f B cell
development. Therefore, this study predicted that Pax5 isoform patterns are differentially
expressed in developing and activated B cell populations, forming unique Pax5
signatures. This study hypothesized that specific Pax5 isoforms modulate Pax5 activity,
thus altering B cell development and activation (see model in Figure 1.6). For example,
Pax5 FL is able to activate genes necessary for B cell development; other isoforms such
as the Pax552 (lacking exon 2) may inhibit the activation o f these genes. Similarly, Pax5
FL is downregulated to allow for plasma cell terminal differentiation. Isoforms lacking
exon 2 may induce plasma cell differentiation.
To address this hypothesis, this study presented four research aims:
1) Identify trout Pax5 isoforms in developing B cells using two-color and tri-color
flow cytometry.

We stained single cell suspensions with combinations o f antibodies against
specific Pax5 domains in addition to markers o f B cell development. We
distinguished populations o f developing B cells across the anterior kidney, blood,
and spleen using established B cell flow cytometric patterns. We analyzed the
frequency o f B cell populations expressing specific Pax5 domains and the
intensity o f Pax5 domain staining within a given B cell population.
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2) Examine trout Pax5 isoform expression after LPS activation using two-color flow
cytometry.

We cultured trout blood and spleen cells in the presence o f B cell mitogen E. coli
lipopolysaccharide. We analyzed Pax5 domain expression and cell proliferation
exemplified by EdU incorporation across tissues.

3) Compare and contrast murine and trout Pax5 isoform expression during
development and activation.

We analyzed mouse bone marrow and spleen cells using two-color and tri-color
flow cytometry. We obtained the frequencies o f developing B cell populations
expressing specific Pax5 domains and compared these to trout B cell populations.

4) Identify the preliminary differences in Pax5 isoform expression in trout resistant
and susceptible to flavobacterium.

We identified B cell populations using the above listed methods. We compared
the frequencies of B cell populations across immune tissues and the frequencies o f
populations expressing specific Pax5 domains between fish. Additionally, we

29

identified changes in B cell populations after LPS activation and we analyzed
differences in proliferating populations based on EdU incorporation.
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Effect o f Pax5 isoforms on activator target genes:

T r o u t A K / M o u s e BM

Effect o f Pax5 isoforms on repressor target genes:

Mature B

PC

Figure 1.6. Model o f Pax5 isoform modulations o f B cell development. Top: During
development, full length (FL) Pax5 is necessary to activate genes promoting B cell
development. Isoforms that inhibit Pax5.FL may inhibit pre-B stages o f development.
Bottom: B cells must downregulate Pax5 repression o f genes necessary for terminal
plasma cell differentiation. Isoforms lacking exon 2 are unable to bind DNA and
therefore cannot inhibit plasma cell differentiation. Isoforms lacking the repressor
domain will permit Pax5 transcription, inhibiting plasma cell differentiation.
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Chapter 2. Manuscript
2.1 Introduction.
The mechanisms of B cell development and activation are highly complex and the
tissues supporting B cell development are uniquely diverse across species. Even with
such species diversity, the stages o f B cell development and molecular players are fairly
conserved. In adult mammals, the bone marrow functions as the primary immune organ
and site o f hematopoiesis. In this tissue, hematopoietic stem cells produce common
lymphocyte progenitors (CLPs) with the competency to form B cells. B cells progress
through stages o f immunoglobulin chain rearrangements, delineated as progenitor-B (proB), pre-B l, large-pre-BII, small pre-BII, and immature B cell stages [13, 15]. Once B
cells acquire functional B cell receptors, they migrate to the spleen (SPL) or other
secondary immune organs where they function as mature B cells, and may encounter
antigen, proliferate and differentiate into antibody-secreting plasma cells.
While previous research has extensively examined mammalian B cell
development, only recently have researchers made significant insights into the teleost B
cell system [2-4, 16, 32, 50, 76]. In contrast to mammals, teleosts lack bone marrow and
alternatively utilize the anterior kidney (AK) as their primary immune organ [2, 3].
Similar to mammals, mature teleost B cells reside in the spleen, encounter antigen, and
differentiate into plasma cells [3]. Additionally, some plasma cells will migrate back to
the primary organ where they will reside as long-lived plasma cells [3].
Although the surfeit o f mammalian serological reagents is unavailable for
deciphering teleost stages o f B cell development, recent research has employed suitable
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alternatives [2, 16, 32, 76]. Conserved transcription factor expression demarcates stages
o f B cell development in both mammals and teleosts [13]. Early developing B cells are
characterized by high expression o f Ikaros, EBF, X bpl, and RAG 1/2 (see Table 1).
Mature B cells express Pax5 combined with low levels o f IgM, while antibody-secreting
cells express high levels o f IgM but no Pax5 [32].
Pax5 is a particularly intriguing transcription factor because o f its conserved role
in regulating B cell commitment in vertebrate species [7, 63]. It is transcribed from an
alternatively-spliced RNA transcript and similar Pax5 isoforms are observed in humans,
mice, trout and amphioxus [2, 71, 72, 77]. Pax5 expression is first observed at the pro-B
stage and Pax5 homozygous deficient B cells will arrest at this stage [5,7]. During B cell
development and activation, Pax5 targets genes necessary for B cell commitment while
downregulating genes necessary for alternative lineages [60-63]. Expression o f Pax5
continues until terminal B cell differentiation. During B cell differentiation, the
transcription factor Blimp 1 represses Pax5, allowing expression o f the B cell activation
marker X bpl [49].
The developmental role o f the full length Pax5 isoform has been described by
many groups, but little is known about the potential function o f alternatively spliced Pax5
isoforms. Using RT-PCR approaches, such isoforms have been observed and examined
in primary cells and malignant cell lines [10-12, 86, 87]. Thus far, no strong correlations
have been observed between isoform type and cell strain or malignancy, although
researchers have demonstrated the differences in transactivating potential o f multiple
isoforms in addition to their modulating effects on full length Pax5 [12, 84],
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Current studies are limited in their ability to correlate Pax5 isoforms with distinct
developing B cell populations due to the use o f pooled cells, either at the RNA level (RTPCR) or protein level (western blot analysis). However, recent research in our lab has
made use o f flow cytometric analyses and antibodies against conserved, B cell specific
transcription factors to begin identifying individual rainbow trout B cell populations at
the various developmental and activated stages [2, 16, 32, 76]. Our research has
demonstrated that early developing B, late developing B, and antibody-secreting B
lymphocyte populations can be characterized through the combinatorial expression o f
specific developmental markers. These expression patterns form “B-cell signatures”, or
flow cytometric patterns that characterize a particular immune tissue.
On the basis o f our prior studies, we hypothesize that certain Pax5 isoforms are
present during limited, specific stages o f B cell development as a means o f modulating
Pax5 activity. We predicted that we could further classify rainbow trout B cell
populations by their patterns of Pax5 domain expression. Here, we report on the flow
cytometric analysis o f both resting and activated trout immune cells using Pax5 domainspecific antibodies. Our results reveal several unique B lymphocyte populations based on
expression o f different Pax5 proteins. We demonstrate that early developing, late
developing, and activated B cells differentially express three Pax5 domains, encoded by
exon 6 (Pax5.E6), exon 10 (Pax5.E10), and the paired domain (Pax5.PD). Examining the
combinatorial expression o f Pax5 proteins with EBF, X bpl-S, and HCmu, we provide
evidence for the first time that early developing populations are present in the blood and
spleen o f rainbow trout.
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2.2 Methods.

Animals and facilities.
Rainbow trout (Onchorhynchus mykiss) were generous gifts from Dr. Steve Kaattari
(Virginia Institute o f Marine Science). Fish were maintained in 100 gallon tanks with a
recirculating system employing biologically-filtered well water. Water was maintained at
12° C. C57BL/6J mice between 3-5 months o f age were obtained from Jackson
Laboratories.

Isolation o f immune cells.
Fresh trout anterior kidney cells were obtained using methods previously described [2].
Briefly, the trout kidney was divided into subsections o f seven vertebrae beginning at the
posterior end (K5). The K1 region was collected in 5 mL sterile HBSS (137 mM NaCl,
5.6 mM D-glucose, 5 mM KC1, 8.1 mM Na2HP04-2H20, and 20 mM Hepes at pH 7.05).
Similarly, mouse bone marrow and mouse and trout spleen were collected in HBSS as
described previously [84]. Single cell suspensions were created by passing cells through a
10 mL syringe followed by filtration through a 40 nm nylon filter (Falcon; BD
Biosciences). Cells were then pelleted at 250 g for 10 minutes and resuspended in cold
HBSS. Cells were then either prepared for culturing (see cell culture and mitogens) or
washed in IX PBS (1.9 mM NaH2P04 H20, 8.1 mM Na2HP04-7H20, 137 mM NaCl, and
2.6 mM KC1, pH 7.4) containing 0.02% sodium azide in preparation for fixation (see
Fixation). Blood cells were washed in cold HBSS and layered onto Histopaque 1077
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cushions (Sigma Aldrich) and spun at 500 g at 4 °C for 45 minutes. The peripheral blood
(PBL) cell layer was removed and cells were either washed in cold HBSS for culturing or
in PBS containing 0.02% azide for fixation.

Cell culture and mitogens.
Freshly isolated trout PBL and spleen cells were cultured at l.OxlO7 cells/mL in trout
culture medium (TCM) consisting o f RPMI 1640 with 10 mM [ -glutamine, 10% FCS, 50
pg/ml gentamicin, 50 pM 2-ME, and the nucleosides adenosine, uracil, cytosine, and
guanosine (final concentration 10 pg/ml; Sigma-Aldrich). Cells were maintained at 18 °C
in the presence o f blood gas and fed every other day with one tenth o f the culture volume
o f a 10X tissue culture cocktail containing 500 pg/ml gentamycin, 10X essential amino
acids (aas), 10X non-essential aas, 70 mM L-glutamine, 70 mg/ml dextrose, 10x
nucleosides, and 33% fetal bovine serum (FBS). B lymphocytes were activated using
mitogen LPS (from Escherichia coli 055:B5, pasteurized for 30 min at 70 °C in distilled
water) at 100 pg/ml. For cell proliferation analysis, cells were incubated in the presence
o f 3 pM 5-ethynyl-2’-deoxyuridine (EdU; Invitrogen) for 17 hours immediately before
collection.

Antibodies.
The polyclonal anti-paired domain (Pax5.PD) antibody (previously called ED-1)
recognizes trout and mouse Pax5 and has been described previously [91]. The rabbit anti
trout Pax5.E6 polyclonal antibody was raised against the injected Pax5 peptide
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HGPGGRDFLRKQMRGDL. The rabbit anti-trout Pax5.E10 polyclonal antibody was
raised against the peptide sequence AASRGAGPAATATASAYDRH. Both antibodies
were generated with GenScript. The monoclonal mouse anti-trout immunoglobulin heavy
chain mu (HCmu 1-14; [92]) was a generous gift from Greg Warr. The tX b p l-S antibody
(referred to here as anti-Xbp 1) binds the stable form o f Xbp 1 protein resulting from
antigenic stimulation and has been described previously [16]. The polyclonal goat-antihuman Pax5.E10 IgG (Pax5-C20) detects the 20 C-terminus amino acids o f human Pax5.
The mouse Pax5.E10 and the rabbit-anti-human EBF IgG (H300; detecting amino acid
residues 1-300 o f EBF1, and reactive with mouse/human EBF2, 3, and 4) were
purchased from Santa Cruz Biotech. The rat-anti-mouse IgM-PE was purchased from BD
Biosciences. Isotype control antibodies included rabbit IgG, goat IgG (Molecular
probes), or mouse IgG (eBiosciences) conjugated to Alexa Fluor 555 or Alexa Fluor 647.
For flow cytometric analyses, unlabeled antibodies were conjugated (Alexa Fluor 555
and/or Alexa Fluor 647) using protein labeling kits according to manufacturer's
instructions (Molecular Probes). Antibody aliquots were stored in 1% BSA at -2 0 °C

Fixation and permeabilization o f cells fo r flo w cytometry.
Cell pellets were resuspended in freshly prepared 1% ice-cold paraformaldehyde (10%
stock, EM-grade; Electron Microscopy Sciences) in PBS and fixed on ice for 15 minutes.
Cells were then washed in IX PBS and resuspended drop wise (while vortexing) in 1 mL
ice-cold 80% methanol. Cells were incubated overnight at -20 °C and stored at -20 °C
until use (up to 3 weeks).
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Flow cytometry.
Cells were removed from -20 °C and an equal volume PBS plus 0.02% azide was
immediately added. Cells were then pelleted and resuspended in 1 mL PBS and 0.02%
azide. Cells were then resuspended in 1 mL permeabilizing solution (BD perm wash in
PBS, BD Biosciences) containing 2% FBS and then incubated in perm wash + 5% FBS at
a concentration o f lx l0 7 cells/mL at 4 °C with gentle shaking. 0.5 x 106 cells were then
transferred to each well on a 96-well polystyrene round bottom plate (Fisher).
Fluorescent Abs were added to the cell suspensions to a final antibody concentration o f
0.5-2 pg/0.5 x 106 cells/50 pi final volume, and cells incubated at 4 °C for 90 min in the
dark with gentle shaking. Cells were next washed in 260 pi o f perm wash + 2% FBS
followed by a 10 min incubation in the dark, shaking, at room temperature. The wash and
incubation was repeated once. For three-color flow cytometry, an indirect staining
approach was used for the third antibody by staining cells with a biotinylated HCmu in
conjunction with steptavidin APC-750 (Sigma). For cell proliferation analysis, the
nucledoside analog EdU and a Click-It kit (Invitrogen) was used according to
manufacturer’s instructions. Cells were pelleted and resuspended in 200 pi perm wash
containing 2% FBS and immediate analyzed. Approximately 30,000 events were
acquired per sample using a BD FACSArray (BD Biosciences). Duplicate samples were
analyzed for each experiment. Experiments were repeated a minimum o f three times.
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Western blot analysis.
Trout cell suspensions were centrifuged in aliquots o f 0.6 x 105 cells or 1.7 x 105 and
pellets were quick-frozen at -8 0 °C. Whole-cell protein lysates were prepared by
resuspending cells in 40 pi o f a sample buffer containing 5% 2-ME and proteins
separated by size using denaturing 12% SDS-PAGE gels. Proteins were transferred onto
a polyvinylidene difluoride (PVDF) membrane (Immobilon-P; Millipore). Membranes
were incubated in blocking solution o f 5% dry milk in PBS containing 0.5% Tween
(PBST) for 1 h, followed by a 2 h incubation in blocking solution in the presence o f
primary antibody: ED-1 (Pax5.PD; lpg/m L final dilution), Pax5.E10 (2 pg/mL final
dilution) or Pax5.E6 (2 pg/mL). Four 5 minute washes in PBST were then followed by a
1 h incubation with the secondary antibody goat anti-rabbit IgG-HRP conjugate
(0.1 pg/ml; Zymed Laboratories) in blocking solution, and membranes were washed four
more times for 5 minutes each in PBST and filters developed using a chemiluminescence
kit (ECL-Plus; GE Healthcare Life Sciences).

Flow cytometric data analysis.
Contour graphs were generated using WinMDI 2-8 (J. Trotter 1993-1998) software at a
2/0.1 threshold/smooth setting. Contour graphs are shown as log algorithms with
intervals of 50%. Quadrants for LPS-activated samples were established by placing Q3
on the double negative population o f the DO sample. All other gates were created by
following contour lines. Statistics were obtained from WinMDI 2-8 software. Arithmetic
means o f population frequencies and standard errors were calculated for each experiment
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using Excel software. The change in relative intensity o f antibody staining over days o f
LPS activation was calculated for each experiment as follows: the average fluorescence
o f a given antibody within the population o f interest was calculated using WinMDI
software and the highest fluorescence o f the antibody within the experiment was given a
100% intensity value. All other average fluorescent values were calculated as a
proportion of the highest fluorescent value. In this manner, we were able to examine the
relative changes in average fluorescence across days o f activation.

2.3 Results and Discussion.
Previous studies have extensively examined Pax5 alternative splicing in immune
tissues across species. However, these studies fail to identify the expression o f Pax5
isoforms in individual developing and activated B cell populations due to the use o f
pooled cells for RT-PCR. Here, we describe an alternative approach using flow
cytometry on freshly isolated rainbow trout tissues. Fixed anterior kidney (AK),
peripheral blood (PBL) and spleen (SPL) cells were permeabilized and stained with
fluorescent antibodies targeting specific B cell markers and transcription factors (Figure
1). Initially, three distinct antibodies were used to explore the presence o f Pax5
subpopulations in trout immune tissues. The Pax5.PD antibody recognized the paired
domain o f Pax5 and has been used in previous studies [2, 16, 32, 76]. A second anti-Pax5
antibody recognized the region encoded by exon 6 o f Pax5, named Pax.E6. A third
antibody, Pax5.E10, is specific to the C-terminal region o f Pax5, encoded by exon 10.
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Figure 1. Diagram o f tro u t Pax5 a n tib o d y specificity. Pax5.PD a n tib o d y re c o g n iz e s t h e paired
d o m a in o f Pax5; Pax5.E6 r e c o n g iz e s a region e n c o d e d by e x o n 6; Pax5.E10 r e co g n iz es t h e Ct e r m in u s (repressor d o m ain ). Each n u m b e r r e p r e s e n ts t h e e x o n e n c o d in g t h e r e sp e c tiv e Pax5
d o m a in .

To demarcate the identified B cell subpopulations, these three Pax5 antibodies
were then used in combination with antibodies for the transcription factors X-box binding
protein 1 (the processed form of X bpl; [16]), EBF [32], and the marker of
immunoglobulin heavy chain mu (HC mu; see Table 1; [2, 76]). Each o f these antibodies
had been used successfully in previous studies to define trout B cell populations. Xbpl is
expressed at high levels in very early B cell stages (CLP, pro-B), is down-regulated
during B cell maturation, and is strongly induced again during terminal B cell
differentiation (see Table 1). HCmu is first expressed in immature B cells and expression
increases throughout terminal B cell differentiation. EBF is highly expressed in CLP and
pro-B cells, followed by downregulation as the B cell matures [16].
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Table 1. Expression o f Pax5 isoform and development markers during B cell stages.
Xbpl-S

Pax5.E10

Pax5.PD
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+

+ /-

+

-

-

-
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H
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Note: H: high; M: medium; L: low. Act.: activated. Expression demarcated by (+) sign, increased
expression by (++) and highest expression by (+++).
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2.3.1. Western blot analysis.
To verify that the three Pax5 antibodies recognized Pax5 protein, western blots o f
freshly isolated rainbow trout spleen, peripheral blood, and anterior kidney were
prepared (Figure 2). Figure 2A shows that the Pax5.PD antibody recognizes the full
length Pax5 protein, a protein with an approximate molecular weight o f 48 kD which
must represent full length Pax5. Using the same antibody, the level o f Pax5 protein is
significantly lower in anterior kidney compared to spleen and blood. Conversely, both
the Pax5.E10 antibody (Figure 2B) and the Pax5.E6 antibody (Figure 2C) stained the 48
kD (full length Pax5) protein in all three tissues. Additionally, Pax5.E10 recognized a
lower molecular weight isoform in all three tissues. These results demonstrate that the
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three Pax5 antibodies recognize the target Pax5 protein and furthermore show that each
antibody recognizes Pax5 in a unique manner across tissues.
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Figure 2. W e s te r n blot analysis o f trou t s p le e n (SPL), blood (PBL), and an terior kidney (AK) using
t h r e e P ax5-specific a n tib o d ie s. Closed Triangle: full length Pax5; o p e n triangle: Pax5 isoform o f
lo w e r m o lec u la r w e ig h t. M olec u lar w e ig h t m arkers (M W M ) s h o w n in kDA o n left. First th r e e
la n es con ta in 0 . 6 x l 0 5 c e lls /la n e; last t h r e e la n es con tain 1 . 7 x l 0 5 c e lls /la n e . A. Pax5.PD stain. B.
Pax5.E 10 stain. C. Pax5.E6 stain.
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2.3.2. Patterns o f Pax5-expressing cells using three distinct trout Pax5 antibodies.
Multiple lymphocyte populations were identified in the anterior kidney, blood and
spleen as shown in Figure 3A. In the anterior kidney, a low and high FSC population is
present, as reported previously [32]. These populations are predicted to contain late and
early developing B cells respectively. Blood was highly variable, consisting o f two to
three lymphocyte populations with unique low and high FSCs. Spleen contained one
main population o f lymphocytes and a smaller population o f low FSC cells.
Permeabilized anterior kidney, peripheral blood, and spleen cells were first co
stained with the anti-Pax5.E6 and anti-Pax5.E10 antibodies and analyzed by two-color
flow cytometry (Figure 3B). For each tissue, three Pax5 subpopulations were identified: a
Pax5.E6 high/Pax5.E10 low population (presumably all isoforms lacking the C-terminus
of Pax5), a Pax5.E6 high/Pax5.E10 high population (cells expressing intermediate to high
levels o f both E6 and E10 regions o f Pax5), and a Pax5.E6 low/Pax5.E10 high population
(cells lacking exon 6 staining). Table 2 lists a summary o f each subpopulation’s mean
frequencies and S.E.s.
When comparing the Pax5.E10 and E6 expression patterns between tissues, the
most abundant population in all three immune tissues consisted o f smaller lymphocytes
that co-stained with both antibodies (the Pax5.E6 high/Pax5.E10 high population). For
PBL and spleen, the frequencies of this co-staining population are consistent with
previous findings [76], and likely represent resting mature B cells. For anterior kidney,
the relatively high frequency o f this population was unexpected.
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Figure 3. Two-color flow cytometry o f anterior kidney (AK), peripheral blood (PBL),
and spleen (SPL). A) FSC and SSC o f gated lymphocyte populations. B) Patterns for
Pax5 using the Pax5.E6 and Pax5.E10 antibodies. Frequencies o f each population are
given as mean % gated lymphocyte population. See Table 2 for all means and SEs.

Using the same two antibodies, a second population o f Pax5-expressing cells had
high Pax5.E6 staining, but lacked a C-terminus (Pax5.E6 high/Pax5.E10 low). This
population was most abundant in anterior kidney (25.0% ± 3.5) and least abundant in
spleen (2.1% ± 0.7). This subpopulation consisted o f large cells (high FSC), supportive
o f their representing an early developing B cell population [32]. The possible presence of
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developing B cells expressing both exon 6 and exon 10 in secondary lymphoid tissues
(PBL and spleen) was investigated and is discussed below.
Conversely, cells that expressed Pax5 proteins that lacked the region encoding
exon 6 but which contained a C-terminus (Pax5.E6 low/Pax5.E10 high population) were
present at low relative frequencies in anterior kidney (0.4%) and spleen (4.4%), and at
high frequencies in the PBL (25%). These findings suggest that isoforms expressing the
C-terminus may be more prominent in activated, terminally differentiating B cells. The
high frequency o f presumably activated/terminally differentiated (Pax5.E6 low/Pax5.E10
high) cells in PBL was unexpected.
Next, trout tissues were stained with the same anti-Pax5.E10 antibody but now in
combination with anti-Pax5.PD (the paired domain-specific antibody). Data are shown in
Figure 4. In the spleen, the majority o f cells co-stained (43.9%) with the two antibodies,
and similarly, PBL showed high (32.8 %) co-staining. Together with the Pax5.E6/E10
data (Figure 3), this suggests that the main Pax5 isoform expressed in secondary immune
tissues is the full-length form (PD+/E6+/E10+).
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Figure 4. Two-color flow cytometry using Pax5.PD and Pax5.E10 antibodies. Mean
frequencies represent % gated lymphocytes. See Table 2 for all means and SEs.

Furthermore, using the same two antibodies, an anterior kidney-unique Pax5positive population was detected which contained the paired domain, but not the Cterminus o f Pax5 (Pax5.PD high/Pax5.E10 low; mean o f 20.3%). While both spleen and
PBL lack this population, both tissues have a population o f Pax5-expressing cells that are
somewhat the opposite: they lack the paired domain, but do contain the C-terminus (PD
low/ E l 0 high). In spleen an average o f 16.4% o f lymphocytes had this phenotype.
Furthermore, these spleen cells exemplified a medium FSC, suggesting they are mature B
cells high in C-terminal Pax5 expression and lower in paired domain Pax5 expression.
Together with the data using Pax5.E6 and Pax5.E10 antibodies, this supports a role for
the C-terminus o f Pax5 in mature or activated B cells.
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Table 2. Average % frequency (S.E.) o f Pax5 subpopulations across im m une tissu es.
Combination

AK

PBL

SPL

Figure*

Pax5.E6 high/Pax5.E10 low

25.0 (3.5)

14.0 (5.4)

2.1 (0.7)

3B

Pax5.E6 high/Pax5.E10 high

34.3 (3.8)

53.1(7.8)

56.4 (5.3)

3B

Pax5.E6 low/Pax5.E10 high

0.4 (0.2)

25.3 (4.3)

4.4 (1.4)

3B

Pax5.PD high/Pax5.E10 high

20.3 (1.7)

0.0 (0.0)

0.0 (0.0)**

4

Pax5.PD high/Pax5.E10 high

40.8 (6.8)

32.8 (13.1)

43.2 (3.8)

4

Pax5.PD low/Pax5.E10 high

0.0 (0.0)**

21.3 (9.9)

16.4(2.8)

4

Pax5.PD high/Pax5.E6 int.

30.3 (4.4)

31.3 (4.1)

44.7 (2.5)

5A

Pax5.PD high/Pax5.E6 high

0.5 (0.2)

6.1 (2.8)

2.4 (0.3)

5A

Pax5.PD low/Pax5.E6 high

27.8 (3.5)

10.7 (3.0)

1.3 (0.4)

5A

Next, two-color flow cytometry was performed using the remaining combination
o f anti-Pax5 antibodies, namely anti-Pax5.PD and anti-Pax5.E6 (Figure 5). All three
tissues show significant populations o f high paired domain, intermediate exon 6
expressing (Pax5.PD high /Pax5.E6 int.) cells: spleen has 44.6%, blood 31.3%, and
anterior kidney 30.3%. This suggests that these cells express full length Pax5 and
represent mature B cells in spleen and blood, and either pre-B or immature B cells in the
anterior kidney. It should be noted that upon tissue isolation, the anterior kidney tissue
contains a fairly high amount of blood, which may affect the anterior kidney B cell
frequencies and explain the relatively high percentage o f paired-domain expressing
(immature and mature B) cells in this tissue.
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Paired-domain-lacking populations were present in all three tissues: in anterior
kidney, 27.8% o f the lymphocytes stained strongly for Pax5.E6, but weakly for Pax5.PD
(Pax5.PD low/Pax5.E6 high). Both PBL (10.7%) and spleen (1.3%) also contain a paireddomain-less Pax5 population (Figure 5). For this antibody combination, the expression
pattern for Pax5.E6 expressing cells follows the patterns shown above (see Figure 3),
with the highest frequency o f Pax5.E6 expressing, but paired domain lacking and Cterminus lacking population (PD -/E6+/E10 -) in the anterior kidney, and the lowest
frequency in the spleen, suggesting that this population contains mostly early developing
B cells. This is supported by FSC data; as shown in Figure 5B, the Pax5.PD low/Pax5.E6
high population in anterior kidney primarily consists o f large, high FSC cells, typically
representing progenitor cells.
Lastly, using Pax5.PD and Pax5.E6 antibodies, a small population o f high costaining cells is present in all tissues, with the lowest frequency in anterior kidney (0.5%)
and highest in the PBL (6.1%; Figure 5A). These cells likely contain full-length Pax5
and have increased Pax5 expression; hence, they may represent activated or terminally
differentiating B cells. This agrees with other reports that observe increased Pax5
expression upon B cell activation [82], as well as with our own observations.
Furthermore, the cell size o f these high co-staining cells (Pax5.PD high/Pax5.E6 high) in
spleen and PBL is considerably larger (medium to high FSC) than those o f the mature B
cells (Pax5.PD high/Pax5.E6 int. cells), supportive o f their being in a more activated
state. The higher frequency o f this subpopulation in the PBL compared to spleen
suggests that PBL contains more activated B cells than spleen.
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Figure 5. Two-color flow cytometry using the Pax5.PD and Pax5.E6 antibodies. A) Flow
graphs depicting mean % frequency o f each Pax5 subpopulation. See Table 2 for all
means and SEs. B) FSC o f each gated Pax5 population. Shaded line: all lymphocytes; red
line: Pax5.PD high/Pax5.E6 int. population; green line: Pax5.PD low/Pax5.E6 high
population; blue line: Pax5.PD high/Pax5.E6 high population. Each corresponding
histograph is present below each flow graph.
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In summary, using the three trout-Pax5 antibodies, we observed several patterns. We
hypothesize that:

1. Some early developing B cells in the anterior kidney already express Pax5 isoforms
that lack the paired domain and the C-terminus. The Pax5 pattern for such cells is P D /E6+/E10- with a B cell signature o f PD -/E6+/E10-/H C m u-/X bpl+/EBF+.
2. The spleen and blood contain a minor population o f early B cell progenitors with the
Pax5 pattern PD-/E6+/E10+ with a B cell signature PD-/E6+/E10+ /H C m u/Xbpl+/EBF+ . These cells are LPS sensitive and differentiate upon LPS activation.
3. The majority o f mature resting B cells express full-length Pax5 protein.
4. A subpopulation o f mature B cells has higher Pax5 C-terminus expression and
activated B cells upregulate full-length forms o f Pax5.
5. Blood may contain more activated B cells than spleen.

2.3.3. Identification of early developing B cells with the Pax5 pattern PD -/E6+/E 10- in
the trout anterior kidney.
To test the prediction that some very early developing B cells in anterior kidney
express Pax5 isoforms that lack both the paired domain and C-terminus, we stained cells
with a combination o f Pax5 antibodies and the tX bpl-S, HCmu, and EBF antibodies.
First, to provide evidence that cells expressing high Pax5.E6 represent early lymphoid
progenitors, we stained anterior kidney cells with both anti-Xbpl and anti-Pax5.E6
antibodies. Results showed that X bpl exhibited perfect co-staining with Pax5.E6 in all
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three tissues (Figure 6): cells that express high Xbpl also express high Pax5.E6, and cells
that express low Xbpl also express low Pax.E6. Next, to distinguish between early
developing B cells and IgM-secreting plasmablasts/pre-plasma cells (both o f which co
stain with Pax.E6 and which express high levels of X bpl), we performed three-color flow
cytometry with anti-Pax5.E6, anti-X bpl, and anti-HCmu antibodies (Figure 6). Three
Pax5.E6/Xbpl co-staining populations were gated: high, intermediate, and no-staining,
named R2, R3, and R4 respectively (see Figure 6A). Histograms were then generated for
HCmu intensity of each gated population (Figure 6B). Importantly, the results show that
a subpopulation of cells with the highest co-staining for E6 and X bpl (R2) lacked HCmu
(Figure 6B, red line), in support o f the prediction that most o f these are early developing
B cells. Cells from the intermediate population (R3) expressed intermediate to high
levels o f HCmu, suggesting these are the late developing B cells, while as expected, the
R4 region also lacked HCmu expression. When the same experiment was repeated using
anti-Pax5.PD instead of Pax5.E6, it was found that PD high cells do not express high
levels o f Xbpl (data not shown). Together with the Pax5.PD data, this suggests that a
subpopulation of anterior kidney cells express high levels o f a Pax5 isoform that contains
exon 6, but lacks a paired domain, while expressing high levels o f X bpl; such cells must
represent early developing B cells, because they do not express immunoglobulin [16].
The FSC histogram supports this assumption, as the high co-staining subpopulation (R2)
consists entirely of larger (high FSC) cells, a characteristic o f early progenitors and
transitional plasma cells. In contrast, the Pax5.PD cells are smaller, more mature cells
(data not shown).
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Formally, it is still possible that the PD -/E6+/X bpl +/H Cm u- cells are antibodysecreting cells that secrete an isotype different from IgM. To further establish early B cell
identity, we used the anti-EBF antibody in combination with anti-Pax5.E6, anti-PD, or
anti-X bpl. A population o f large cells (high FSC) that co-stained E6 and EBF, and Xbpl
and EBF, was detected in anterior kidney, supporting that these are early developing B
cells in the anterior kidney with the Pax5 pattern PD -/E6+/E10-.
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Figure 6. Three-color flow cytometry for Pax5.E6, HCmu, and Xbpl in AK, PBL, and SPL. A)
Flow graphs depicting the coexpression o f Pax5.E6 and tX bpl. Regions R2, R3, and R4 utilized
for histogram analysis. B) Histogram o f number o f cells within Pax5.E6/Xbpl regions expressing
intensities of HCmu. C) Histogram o f FSC for cells within Pax5.E6/Xbpl regions. Grey shaded
line: all gated lymphocytes; red line: R2; green line: R3; blue line: R4.

2.3.4. Identification o f early developing B cells with the PD-/E6+/E10+ Pax5 pattern in
the trout spleen.
Next, the presence o f early developing B cells (Pax5.E6 high/Xbpl high) was
tested in secondary immune sites. As expected, a population o f mature B cells (high
HCmu-expressing cells) was observed in the intermediate (R3) population in both spleen
and PBL (Ligure 6B; green line). However, the highest co-staining population (R2, red
line) contained both HCmu-staining and non-HCmu-staining populations. The HCmustaining population likely includes IgM antibody-secreting cells, either transitional or
mature plasma cells [32].
To address the possibility that some o f the Pax5.E6 high/Xbpl high/ HCmu
negative (R2) population in spleen contained early B cell progenitors, cells were stained
with both Pax5.E6 and the early B cell marker EBL. Indeed, a small population o f E6
high/EBL high cells was detected (data not shown). This supports our hypothesis that
trout spleen cells house a small population o f early developing B cells.
We additionally tested if cells high in Pax5.E10 expression also co-stained EBF.
In the anterior kidney, none o f the EBF positive cells express HCmu [32]. In both the
anterior kidney and spleen, EBF co-stained with cells expressing the Pax5-C terminus,
suggesting that some early developing B cells have a Pax5 pattern PD -/E 6+/E 10+.
These cells likely represent a population o f early progenitor B cells as they were larger in
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size, but did not costain with cells expressing the highest E6 and X bpl. In the spleen, this
subpopulation had a frequency o f 2-4%. Hence, our prediction that spleen contains a
population of early developing B cells with the Pax5 pattern PD-/E6+/E10+ holds true.
This population is different from the PD-/E6+/E10- population (Figures 3B and 5).

2.3.5. Differential expression o f Pax5 isoforms during in vitro LPS-activation o f trout
spleen cells.
Three predictions needed to be tested in spleen cells: (1) that resting mature
spleen cells express full length Pax5, (2) that spleen cells contain a small population o f
early developing B cells with the Pax5 pattern PD-/E6+/E10+ which differentiate upon
activation, and (3) that activated B cells have increased expression levels o f full-length
Pax5. To test these predictions, we cultured spleen cells in the presence o f mitogen LPS
and analyzed cells on days 2, 4, and 7 after activation (see Figure 7).
Figure 7A displays the change in frequency o f the major Pax5 lymphocyte
population, the population that co-stained with Pax5 antibodies recognizing exons 6 and
10 (Pax5.E6 and Pax5.E10), and which presumably express the full-length form o f Pax5.
The abundance o f this co-staining subpopulation decreased significantly as cells became
activated by LPS, with frequencies dropping from 52.7% on day 0 to 21.0% on day 7 (see
Table 3 for mean frequencies and SEs). Conversely, a population o f cells staining for
exon 10 but not exon 6 (Pax5.E6 low/Pax5.E10 high), increased in frequency, from 8.4%
on day 0 to 20% by day 7. A similar increase was observed when the Pax5.E10 antibody
was used in combination with Pax5.PD: cells staining with exon 10 but not P P . This
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Pax5.PD low/Pax5.E10 high subpopulation increased from 14.6% on day 0 to 30.7% on
day 7 (Figure 7B). In agreement with these patterns, the Pax5.PD/Pax5.E10 co-staining
population (containing PD and exon 10) decreased in frequency during activation,
demonstrating that cells stained with Pax5.PD decrease in frequency. Figure 7C
represents the change in cell populations expressing paired domain and exon 6 across
days o f activation. The frequency o f the Pax5.PD high/Pax5.E6 low subpopulation also
decreases during activation (consistent with the trends observed in Figure 7B) as does the
Pax5.PD high/Pax5.E6 high subpopulation. The graphs also demonstrate a noteworthy
decrease o f the Pax5.PD low/Pax5.E6 high early developing population (Figure 7A and
7C red circles) previously described in this study.
Together, these findings suggest that the frequency o f cells expressing the paired
domain decreases during activation. However, the frequency o f cells expressing the Pax5
C-terminus, but not the paired domain (Pax5.PD low/Pax5.E10 high), increases during
activation. Lastly, the Pax5.E6 high early developing cells decrease during activation,
suggesting they differentiate upon LPS activation, although cell death could also account
for this decrease.
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Figure 7. Two-color flow cytometry for cells cultured in E. coli LPS. Days (D) represent
day fixed after LPS exposure. Red circles indicate Pax5.E6 high early developing cells.
Frequencies represent average frequency o f cells in quadrant. A) Cells stained with antiPax5.E6 and anti-Pax5.E10 antibodies. B) Cells stained with anti-Pax5.PD and antiPax5.E10 antibodies. C) Cells stained with anti-Pax5.PD and anti-Pax5.E6 antibodies.
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To explore these patterns further, we measured if the changes in a population’s
cell frequency during activation were accompanied by changes in the relative intensity of
Pax5 exon 10 expression in individual cells. We focused on two small, but dynamic,
populations. First, the predicted early developing Pax5.E6 high and Pax5.E10 low
population was analyzed (Figure 8). For this population o f cells, the intensity o f Pax5.E6
did not change significantly during LPS-activation, while the intensity o f Pax5.E10
expression increased throughout the activation period. Based on earlier findings, the
increase in Pax5.E10 supports the idea that these cells are differentiating during
activation. A second minor population Pax5.E6 low/Pax5.E10 high (predicted to be
mature or activated B cells), also showed little change in intensity o f exon 6- expression,
while the intensity of E10 again increased throughout the activation period.
Together, these data demonstrate that in addition to increased cell frequency of
E10 staining cells during activation, cells also exhibit a significant increase o f Pax5 Cterminus intensity. This could be an indication that cells are not losing usage o f exon 6
expression as much as they are accumulating more Pax5 protein that contains a Cterminus.

58

Pax5.E10
—

»Pax5.E6

120

100
80
■>

P a x S .E lO

60

■Pax5.E 10

40

• PaxS.Eb

20

0

Figure 8. Change in relative intensity o f Pax5.E6 and Pax5.E10 expression in LPSactivated SPL cells. Top graph: change in relative expression o f the Pax5.E6
high/Pax5.E10 low population. Bottom graph: change in relative expression o f the
Pax5.E6 low/Pax5.E10 high population.
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Similarly, when experiments are performed using Pax5.E10 and Pax5.PD
antibodies, the high co-staining population o f cells upregulate Pax5.E10 expression as
they reach terminal B cell differentiation, while levels o f paired domain in the cell remain
relatively constant during that period (Figure 9). Furthermore, Pax5.PD low/Pax5.E10
high cells not only increase their Pax5.E10 intensity during activation, but
simultaneously decrease their Pax5.PD intensity. This further emphasizes an increased
role for the C-terminus and decreased role for the paired domain as early activated B cells
differentiate toward antibody-secreting cells.
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Figure 9. Change in relative intensity o f Pax5.PD and Pax5.E10 expression in LPSactivated SPL cells. Top graph: change in relative expression o f the Pax5.EPD
high/Pax5.E10 low population. Bottom graph: change in relative expression o f the
Pax5.PD low/Pax5.E10 high population.
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Lastly, we analyzed changes in Pax5.PD/Pax5.E6 intensity during LPS activation
(Figure 10). Upon LPS-activation, the main Pax5 population, which represents mature B
cells (Pax5.PD high/Pax5.E6 int.), had increased intensity o f both Pax5.PD and Pax5.E6
domains. This increase in intensity corresponded with a transient increase in frequency of
cells expressing high levels o f both paired domain and exon 6 through day 4 o f LPS
activation. These patterns suggest that early activated B cells increase the amount o f fulllength Pax5 protein in their cells prior to downregulation o f Pax5 during the final
differentiation towards plasma cells.
The minor population o f exon 6 possessing, but paired domain-lacking cells
(Pax5.PD low/Pax5.E6 high) appears to lose even more Pax5.PD expression as the cells
become more activated. Pax5.E6 expression per cell also decreases during activation.
This population disappears over time, and consequently, this population could not be
analyzed on day 7 after LPS activation. It is possible that this population represents Tplasma cells, which also have low expression o f Pax5.PD [32]. Alternatively, a
subpopulation o f these E6 high cells is early developing cells because they co-stain with
EBF and possibly develop into mature B cells during activation.
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Figure 10. Change in relative intensity o f Pax5.PD and Pax5.E6 expression in LPSactivated SPL cells. Top graph: change in relative expression o f the Pax5.EPD
high/Pax5.E6 int. population. Bottom graph: change in relative expression o f the
Pax5.PD low/Pax5.E6 high population.

2.3.6. Expression of Pax5 subpopulations with HCmu during LPS-activation.
So far, our findings suggested that Pax5 isoforms lose their paired domain during
B cell activation, while some of these cells maintain their Pax5 C-terminus. To further
test the validity o f these findings, we stained spleen cells with combinations o f Pax5
antibodies and the IgM-detecting (HCmu) antibody during LPS-activation, as presented
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in Figure 11. Figure 11A and 1 IB demonstrate unique flow cytometry patterns for
Pax5.E6/HCmu expression and Pax5.E10/HCmu expression, respectively.

Figure 11. Two-color flow cytometry contours o f LPS-activated SPL cells stained with anti-Pax5
and anti-HCmu antibodies. D: Day A) Cells stained with anti-Pax5.E6 and anti-HCmu antibodies
across days in culture. B) Cells stained with Pax5.E10 and HCmu across days in culture.

The majority o f Pax5.E6 positive cells co-stained for the HCmu antibody, while
Pax5.E10 positive cells split into a IgM-expressing (HCmu high) and IgM-lacking
(HCmu low) population (Figure 1 IB). As the graphs demonstrate, both the Pax5.E6
high/HCmu high population and the Pax5.E10 high/HCmu high population increase
levels o f HCmu per cell during the activation period, suggesting that cells expressing
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both Pax5 domains (E6 and E10) are activated B cells. It is unlikely that any o f the high
IgM-expressing (HCmu++) cells have differentiated into plasma cells by day 7 [16, 32],
and this corresponds with continued expression o f Pax5 up to that time point. However,
EdU proliferation analyses reveal that some o f these cells are plasmablasts that express
all three Pax5 antibodies (data not shown).
Two interesting additional observations can be made: first, when staining with
Pax5.E10, there is a very significant shift from most cells being HCmu+ and Pax5.E10
double-positive cells, to almost equal numbers o f IgM+ and IgM- cells that all contain the
C-terminus o f their Pax5 protein. Although some these IgM- cells additionally express
the paired domain (data not shown), the frequency o f the Pax5.E10+/IgM- population is
consistently higher than the Pax5.PD/IgM- population. This further supports an important
role for exon 10 during terminal B cell differentiation.
A second observation is that a minor, high Pax5.E6/low HCmu staining
population is downregulated during B cell activation and is undetectable by D7. This is
likely the same population observed earlier, Pax5.PD low/Pax5.E6 high (Figure 7).
Hence, during terminal B cell differentiation, a population o f paired domain-lacking,
exon 6 expressing, but IgM-lacking B cells, (PD-/E6+/H cm u-) disappears. It is possible
that this population represents one o f the two early developing B cell populations (P D /E6+/E10+ or PD -/E6+/E10-) described above.
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Table 3. A verage % frequency (S.E.) o f LPS activated SPL cells.

Pax5.E6/Pax5.E10

Q1 (E6+/E10-)

Q2 (E6+/E10+)

Q3 (E6-/E10-)

Q4 (E6-/E10+)

DO

1.0 (0.3)

52.7(11.5)

37.9 (12.1)

8.4(1.6)

D2

1.5 (0.9)

44.9 (2.0)

44.6 (2.5)

9.1 (1.5)

D4

1.3 (0.9)

39.0(5.3)

44.8 (12.0)

14.9 (7.3)

D7

2.5 (1.1)

21.0 (0.9)

56.5 (7.3)

20.0 (9.3)

Pax5.PD/Pax5.E10

Q1

Q2

Q3

Q4

DO

0.3 (0.1)

51.0 (5.4)

34.1 (8.1)

14.6 (4.0)

D2

0.1 (0.0)

39.6(1.3)

40.7 (2.5)

19.6(3.3) '

D4

0.0(0.0)

33.9 (4.6)

42.0 (1.2)

23.8 (5.6)

D7

0.1 (0.0)

13.0 (0.8)

56.2 (12.3)

30.7(13.0)

Pax5.PD/Pax5.E6

Q1

Q2

Q3

Q4

DO

27.7(5.1)

21.9 (4.3)

48.4 (1.5)

2.0 (0.3)

D2

14.9 (5.6)

23.1(3.7)

60.1 (5.0)

2.0 (0.5)

D4

6.4 (1.8)

27.3 (5.3)

64.3 (6.0)

1.9 (0.6)

D7

2.6 (0.4)

11.8 (3.3)

83.0 (3.7)

2.6 (1.0)

HCmu/Pax5.E6

Q1

Q2

Q3

Q4

DO

2.7 (1.3)

36.1(3.8)

48.7 (3.6)

12.5(2.6)

D2

1.2 (0.6)

33.2 (4.7)

57.0 (6.3)

8.6 (2.8)

D4

1.4 (0.8)

33.1 (4.3)

57.1(5.6)

8.4 (2.7)

D7

5.5 (3.1)

18.7(4.1)

68.8(6.7)

7.0 (2.1)

HCmu/Pax5.E10

Q1

Q2

Q3

Q4

DO

1.7 (0.4)

39.3 (4.4)

38.9 (4.9)

20.1(1.0)

D2

0.5 (0.1)

30.5 (3.7)

53.5 (6.4)

15.5 (2.9)

D4

2.6 (0.7)

30.1 (4.7)

56.2 (5.1)

11.1 (1.2)

D7

8.5 (1.9)

9.4(2.8)

74.4 (6.8)

7.8 (2.2)

Note. D: day fixed after LPS activation.
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2.3.7. Comparative expression of Pax5 subpopulations in the mouse and rainbow trout.
Much o f the previous work on Pax5 alternative splicing has been performed using
murine models. To further test our findings in the teleost model and to elucidate
important evolutionary differences between teleosts and mammals, we performed twocolor flow cytometry on freshly isolated mouse bone marrow (the functional equivalent
to the anterior kidney) and mouse spleen cells. Cells were stained with a mouse
equivalent of anti-Pax5.E10 antibody (C20) and the conserved anti-Pax5.PD antibody
(ED-1). We do not currently have a mouse equivalent o f the Pax5.E6 marker and
therefore cannot use this for comparison. Elowever, to further ascertain the identity o f
early developing, Pax5-expressing-B cell subpopulations, cells were stained with antiEBF and anti-HCmu in combination with Pax5 antibodies.
Based on our findings in trout, we predicted that the mouse bone marrow would
possess an early developing subpopulation with the Pax5 pattern P D -/E 10+/HCm u/EBF+. To test this prediction, we first stained mouse bone marrow cells for Pax5.PD and
Pax5.E10. Figure 12 demonstrates that the flow cytometry patterns for bone marrow cells
stained with this combination are different from the patterns identified earlier for trout
anterior kidney cells. In contrast to anterior kidney, the bone marrow maintains a high
frequency (27.0%) o f cells lacking the paired domain (Pax5.PD negative) but expressing
the Pax5 C-terminus (Pax5.E10 high cells). As presented earlier, the anterior kidney
maintains a high frequency (20.3%) o f cells expressing the paired domain but with low
C-terminus expression. Previous research demonstrates that murine bone marrow consists
o f more early developing B cells and fewer late developing B cells than the trout anterior
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kidney [32]. The higher frequency o f the Pax5 C-terminus expressing cells may be
attributed to the fact that mouse bone marrow contains more early developing B cells.

M ouse

Trout

«*
->

PaxB.ElO

Figure 12. Two-color flow cytometry o f mouse bone marrow (BM) and spleen (SPL)
cells, and trout antierior kidney (AK) and spleen (SPL) cells stained with anti-Pax5.PD
and anti-Pax5.E10 antibodies.

Surprisingly, when the PD/E10 combination in mouse spleen was tested, a small
population of larger (high FSC) cells expressing the Pax5 C-terminus, but not the paired
domain was identified. This population is similar to the small PD -/E10+ population
identified in trout spleen. While the frequency o f the mouse spleen Pax5.E10 high
population is 0.9%, the trout spleen Pax5.PD low/Pax5.E10 high subpopulation is 16.4%.
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The difference in frequencies may be explained by the earlier finding that trout spleen
consists o f a Pax5.E10 high mature/activated B cell population in addition to a Pax5.E10
high early developing B cell population.

M o u s e BM

M o u s e SPL
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Figure 13. Two-color flow cytometry contour graphs for mouse and trout immune tissues.
A) Mouse bone marrow (BM) and spleen (SPL) using anti-EBF and anti-Pax5.E10
antibodies. B) Trout anterior kidney (AK) and SPL using anti-EBF and anti-Pax5.E10
antibodies.
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To test whether mouse Pax5.E10 high populations represented early developing B
cells, we stained mouse cells with a combination o f the anti-EBF and anti-Pax5.E10
antibodies. Remarkably, in both mouse bone marrow and spleen, the Pax5.E10 high/EBF
high populations co-stained EBF and exemplified flow cytometry patterns comparable to
the trout anterior kidney and spleen (Figure 13). In mouse spleen, the frequency o f the
Pax5.E10 high population was 2-4%. In comparison, in trout spleen we had observed two
EBF high populations that co-stained with Pax5.E10, one at 2.9% and one at 2.0%.
Together with the previous data, these patterns suggest that both species have a
population o f early developing B cells that express their Pax5 C-terminus, but do not
express the paired domain (Figure 12). Furthermore, in mouse as in trout, the Pax5.E10
high/EBF high population does not co-express FICmu (data not shown). From these
findings, we can conclude that although mouse and trout may differentially utilize
isoforms containing the C-terminus during B cell maturation and activation, both species
possess an isoform containing exon 10, but lacking paired domain, during early B cell
development.

2.3.8. Concluding Remarks.
In conclusion, we have demonstrated that antibodies targeting three distinct
domains o f Pax5 can be used with flow cytometry to identify individual B cell
populations in rainbow trout using flow cytometric analysis. Early developing B cells,
and potentially common lymphocyte progenitors, lack the paired domain and are
characterized by high exon 6 expression. Early pro-B cells may similarly have high exon
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6 expression, but are further characterized by high exon 10 expression. These cell
populations are observed in both the anterior kidney and the spleen.
The majority of mature B cells expressed in the spleen are characterized by full
length Pax5 expression. However, there is an additional population o f mature/activated B
cells that are low in Pax5 paired domain and high in Pax5 C-terminus. By staining LPS
activated cells, we have demonstrated that terminal differentiation is characterized by the
loss o f the paired domain and potential maintenance or increase o f the C-terminus.
Additionally, we have shown that activated B cells, there is a transiently increase in the
expression o f full length Pax5 expression.

Finally, using a murine model, we have

provided support for our novel finding that Pax5 isoforms lacking the paired domain are
observed in early developing B cell populations. Furthermore, we have demonstrated that
the use o f these isoforms in developing B cells is potentially conserved between
mammalian and teleost species.
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Chapter 3- R and S Fish
3.1 Introduction.
Flavobacterium psychrophilum is the pathogen responsible for bacterial cold
water disease (BCWD), a sickness which contributes to high mortality rates in
aquaculture [93]. Recent work at the National Center for Cool and Cold Water
Aquaculture has attempted to identify traits o f rainbow trout resistant to BCWD and to
selectively breed resistant trout through three generations [94]. The selection process has
proved promising, but it has yet to be uncovered which molecular mechanisms underlie
trout flavobacterium resistance. One potential mechanism contributing to resistance is a
change in humoral immune response. Therefore, to investigate the humoral immunity o f
resistant trout, our lab is currently utilizing flow cytometry to compare and contrast the B
cell populations composing the resistant and susceptible trout immune tissues. In this
chapter, we present key preliminary results regarding the proliferating, developing, and
activated B cell populations.

3.2 Results.
To further understand the molecular basis o f bacterial cold water disease
resistance, our lab examined B cell development and activation in trout bred to be
genetically resistant (R line) or susceptible (S line) to flavobacterium. We first created
single cell suspensions from either freshly isolated R line or S line trout immune tissues.
We then fixed, permeabilized, and stained cells with antibodies targeting developmental
transcription factors and HCmu. We additionally performed primary cell culturing o f
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cells in the presence o f mitogen LPS and proliferation marker EdU prior to cell fixation.
Two-color flow cytometry was performed to analyze differences in cell proliferation and
B cell development and activation.

3.2.1 Differences in LPS activated B cell proliferation.
To test the differences in B cell proliferation, R line and S line trout blood and
spleen were LPS activated over seven days. Prior to collection, cells were cultured in the
presence o f nucleoside analog EdU (Invitrogen). The cells were then fixed,
permeabilized, and stained with either the anti-Pax5.E10 or Pax5.E6 antibodies (for
methods, see Chapter 2).
As expected, the majority o f proliferating blood and spleen cells expressed both
exon 6 and exon 10 o f Pax5, suggesting these cells were in the plasmablast stage o f
activation (see Q2 of Tables 4 and 5). The preliminary results do not suggest a trend in
the frequency o f proliferating B cells expressing Pax5.E10 versus the frequency o f
proliferating cells expressing Pax5.E6. However, observations from one experiment may
suggest that more proliferating cells are Pax5.E10 negative across activation than
Pax5.E6 negative. This means that as B cells terminally differentiate, they lose isoforms
containing exon 10 o f Pax5. Although Pax5.E10 is maintained in a higher frequency o f
cells during activation than Pax5.E6, it could be the case that only Pax5.E6 is expressed
later in the transient plasma cell stage.
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Table 4. Average frequency of proliferating and non-proliferating Pax5.E10 cells (S.E.).
RPBL

Q1
E10+/EdU-

D2
19.3
(7.9)

S-PBL

RSPL

S-SPL

D4
38.5
(9.0)

D7
46.2
(11.7)

D2
23.9
(10.9)

D4
38.9
(9.3)

D7
41.1
(14.7)

D2
34.4
(9.0)

D4
28.7
(5.4)

D7
18.1
(3.1)

D2
50.3
(10.4)

D4
47.4
(9.2)

D7
27.2
(5.1)

Q2
E10+/EdU+

0.3

1.7

0.7

0.2

3.7

2.6

0.2

1.2

0.4

0.3

1.1

0.7

(0.2)

(0.4)

(0.4)

(0.0)

(1.2)

(1-3)

(0.1)

(0.5)

(0.2)

(0.0)

(0.5)

(0.3)

Q3
E10-/Edll-

80.1
(7.7

59.3
(8.7)

53.0
(11.3)

75.8
(11.0)

56.7
(10.0)

54.8
(13.4)

65.4
(8.9)

69.8
(4.8)

81.4
(3.3)

49.4
(10.4)

51.1
(9.5)

71.9
(5.20

Q4
E10-/EdU+

0.3
(0.2)

0.5
(0.3)

0.0
(0.0)

0.1
(0.0)

0.7
(0.5)

1.4
(1.3)

0.1
(0.0)

0.3
(0.2)

0.0
(0.0)

0.0
(0.0)

0.3
(0.2)

0.2
(0.2)

Note. S.E. represented in parentheses. D: Day o f fixation after LPS activation

Table 5. Average frequency of proliferating and non-proliferating Pax5.E6 cells (S.E.).
R-PBL

R-SPL

S- PBL

S-SPL

D2
33.31
(11.4)

D4
42.0
(12.1)

D7
47.7
(4.6)

D2
32.8
(6.9)

D4
38.3
(10.4)

D7
49.5
(8.7)

D2
40.4
(10.3)

D4
32.9
(6.6)

D7
25.9
(7.3)

D2
43.0
(10.1)

D4
39.7
(7.0)

D7
31.9
(3.8)

Q2
E6+/EdU+

0.1

0.4

0.1

0.1

2.1

1.2

0.2

0.7

0.3

0.2

0.8

0.5

(0.0)

(0-2)

(0.0)

(0.0)

(2.4)

(0.7)

(0.0)

(0.3)

(0.2)

(0.0)

(0.3)

(0.3)

Q3
E6-/EdU-

66.6
(11.4)

57.5
(12.2)

52.1
(4.6)

67.1
(6.9)

48.7
(12.6)

49.3
(9.4)

59.3
(11.8)

66.4
(6.3)

73.8
(7.4)

56.7
(10.1)

59.5
(6.8)

67.5
(3.6)

Q4
E6-/EdU+

0.0
(0.0)

0.1
(0.0)

0.0
(0.0)

0.0
(0.0)

0.0
(0.0)

0.0
(0.0)

0.0
(0.1)

0.1
(0.1)

0.0
(0.0)

0.0
(0.0)

0.1
(0.0)

0.1
(0.1)

Q.1
E6+/EdU-

Note. S.E. represented in parentheses. D: Day o f fixation after LPS activation
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Total proliferation o f cells independent o f Pax5 expression was also identified for
each experiment. The results show that blood had the highest proliferation and expressed
proliferating cells differently between resistant and susceptible lines o f trout. The
frequency of proliferating cells during activation is higher in the S line blood versus the R
line blood (Figure 14A). In contrast to blood, there was very little cell proliferation in the
spleen and there appeared to be no differences in spleen cell proliferation between the R
line and S line (Figure 14B). These findings were unexpected due to initial observations
during our earlier experiments with younger trout. In these first experiments, we observed
greater increases in cell proliferation in blood and spleen o f the R line compared to the S
line. However, in later experiments with older fish, we observed the opposite for blood
and the lack of proliferation in spleen cells. One possible explanation for this change
could be that the older resistant fish contained more erythrocytes than susceptible fish.
The increased presence o f erythrocytes in these R line spleens could possibly alter the
ability o f cultured lymphocytes to uptake the EdU. A consequence o f this would be a
false negative proliferation result. However, it is still possible that earlier experiments
were outliers. A larger sample size will be necessary before any conclusions can be
drawn for these proliferation studies.

3.2.2 Differences in B cell development.
Our initial study o f Pax5 isoform expression in B lymphocytes revealed a
population o f early developing B cells lacking the Pax5 paired domain but expressing
Pax5 exon 6. This population was found (at different frequencies) in the anterior kidney,
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blood, and spleen. The presence o f this developing population in both primary and
secondary immune tissues lead us to believe it would be an interesting candidate
population to compare between R and S lines o f trout. We therefore analyzed the
frequency of cells in the Pax5.PD low/Pax5.E6 high population across tissues. By using
this combination, we ensured that we were examining an early developing Pax5
population lacking in paired domain. The results show an interesting trend: the
developing population is present at a higher frequency in R line anterior kidney and blood
compared to S line (Figure 15A). Conversely, in spleen, the developing population has a
higher frequency in the S line than the R line.
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DO

D2

D4

D7

Figure 14. The average frequency o f proliferating cells in R line and S line blood (A) and spleen

(B).

There are several potential explanations for the differences in developing B cell
populations. Previous studies demonstrated increases in murine spleen hematopoiesis at
the expense of bone marrow hematopoiesis after viral or bacterial infection [95-97]. It is
possible that infection in rainbow trout induces a response resulting in increased splenic
B cell development. In contrast to spleen, the increase in developing B cells in the
anterior kidney and blood o f resistant fish could provide a means to protect against
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infection. If this is true, then this follows our expectation that susceptible fish have a
lower frequency o f developing B cell populations in the anterior kidney and blood.
However, this is again speculation; larger sample sizes and statistical analysis will reveal
if these findings reflect a true biological phenomenon.

B

Figure 15. Differences in early developing (A) and activated (B) B cell populations in R
and S lines of trout.
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3.2.3. Differences in blood B cell activation.
Using three-color flow cytometry, we previously demonstrated that a population
of blood cells expressing high paired domain (Pax5.PD) and Pax5 exon 6 (Pax5.E6) were
additionally high in HCmu expression. The HCmu expression indicated this population
was highly activated. Interestingly, this population had the highest frequency in the
blood, suggesting a role for more activated B cells in this tissue. Therefore, we decided to
investigate changes in this activated population between R and S line blood using twocolor flow cytometry for Pax5.PD and Pax5.E6 expression. The results demonstrate a
slight increase in the frequency o f the activated population in resistant fish (Figure 15B).
An increase in activated cells could be a mechanism allowing the fish to have B cells
more readily available to fight pathogen. However, this result does not likely represent a
statistically significant finding as the standard error was large in both resistant and
susceptible fish samples. Therefore, in our preliminary experiments there appears to be
no difference in the Pax5.PD/Pax5.E6 population between trout strains. However, as the
blood is a highly variable tissue and our sample size is small, it may be premature to
conclude no differences exist.

3.2.4. Concluding remarks.
Our preliminary results suggest two major differences in B cell populations
between R and S lines o f trout. First, the susceptible fish may express a higher frequency
o f proliferating blood plasmablasts after day four o f LPS activation, as demonstrated by
cells’ combinatorial expressions o f Pax5.E10 (or Pax5.E6) and EdU. The reason for
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higher proliferation in susceptible trout is unclear, but one potential explanation could be
that the fish are inducing a greater humoral response to pathogen more frequently than
the resistant fish. Our preliminary data also suggest a role for early developing B cells in
anterior kidney and blood (but not spleen) in resistant line trout. With a higher frequency
o f early developing B cells, resistant fish may be able to more readily fight pathogen by
inducing a more rapid developmental program.
Although no differences were identified when examining the activated
Pax5.PD/Pax.E6 high B cell population, our observations indicate there still may be
differences in activated B cells between fish strains. The data from other Pax5
combinations in addition to LPS studies suggest resistant fish more often express higher
frequencies o f cells in many o f the activated B cell populations (data not shown). The
spleen will be a particularly interesting tissue to examine in this context and other studies
o f resistant fish have already demonstrated that spleen sizes, particularly larger spleens,
correspond to flavobacterium resistance [98]. Overall, the potential to identify differences
in developing B cell populations between resistant and susceptible trout is promising.
Identifying the molecular context o f flavobacterium resistance is essential for
understanding the implications o f genetic alterations and is invaluable knowledge for
future aquaculture engineering.
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Chapter 4-Discussion.
The expression and function o f Pax5 isoforms remains an enigma in the
immunological community. Thus far, the use o f RT-PCR has enabled researchers to
identify multiple transcripts that encode N- and C-terminal Pax5 isoforms, many o f
which are conserved across species. Such studies have revealed that trout, mice, humans,
and amphioxus all express a subset o f Pax5 isoforms that lack either the paired domain or
C-terminus. Transfection studies have further demonstrated these isoforms are not only
translated, but also have functional transactivating capabilities. Despite these advances,
research has yet to demonstrate a definitive pattern o f Pax5 isoforms across cell lines,
immune tissues, and malignancies. Furthermore, investigators still do not understand the
biological function o f these distinct isoforms or the relevance o f their expression patterns.
Here, for the first time, we support a role for Pax5 isoforms by demonstrating differential
isoform expression in individual developing and activated B cell populations in rainbow
trout. Although our flow cytometric approach has limitations, it reveals that distinct early
developing and activated populations can be characterized by their combined expression
o f transcription factors, surface markers, and Pax5 domains. Collectively, we call this
expression pattern the “Pax5 signature” o f a tissue.

4.1 The Pax5 patterns o f early developing B cells.
The anterior kidney is a complex immune tissue composed o f early developing,
late developing, and long-lived plasma cells ([2, 3, 32, 76]. Previous studies have
separated anterior kidney populations by their diverse expression o f EBF, HCmu and
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most relevantly, the Pax5 paired domain [32]. The majority o f early developing B cells
are characterized by high FSC, high EBF expression, and low Pax5 paired domain
expression [32]. As the paired domain is essential for the transcription o f genes
necessary for B cell fate [8, 60], it is remarkable that our results identified a large
population of the earliest developing B cells, including potential CLPs, that express
isoforms o f Pax5 that contain exon 6 but lack both the paired domain and the Cterminus. These cells have a Pax5 pattern PD-/E6+/E10- with a B cell signature PD/E6+/E10-/HCmu-/Xbpl+/EBF+. This high FSC population consistently co-stained high
levels o f X bpl and EBF, and remained negative in heavy chain immunoglobulin
expression, suggesting it constituted the earliest o f B cell populations (see Table 1).
Most importantly, the earliest B cell population suggests a conserved
developmental role for Pax5 isoforms lacking exon 2 and exon 10. In general, one
proposed function for differential isoform expression is to regulate the activity o f full
length proteins by competing with full length isoforms for protein/DNA binding partners.
This mechanism has been observed for isoforms o f the alternatively spliced transcription
factor Ikaros (reviewed in [99]). Supporting this hypothesis, studies o f murine Pax5 show
that the Pax5-d isoform may act as a dominant negative regulator; when co-transfected
with full length Pax5 in vitro, it downregulates the activity o f the full length protein [84].
Cross-species analyses reveal vast differences in Pax5 isoform expression; however,
almost all species examined share isoforms lacking a functional paired domain. Recent
research suggests that although Pax5 isoforms lacking a paired domain are incapable of
binding DNA, they may still indirectly regulate transcription at anti-sense promoters via
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the Pax5 partial homeodomain located on exon 6 [100]. Research has yet to elucidate if
this mechanism o f regulation is prominent in early developing B cells.
The lack o f exon 10 expression in the earliest developing B cells demonstrates
that in addition to a lack o f DNA binding capability, early B cells also lack a repressor
domain. Although the function o f the repressor domain remains poorly understood,
studies demonstrate that deletion o f the last 22-33 amino acids o f the Pax5 C-terminus
results in increased Pax5 transactivating potential. Thus, the Pax5 transactivation domain
may be strongly regulated by this adjacent inhibitory domain [71]. The lack o f this
domain in early developing cells suggests a potential role for this inhibitory domain in B
cell activation, a hypothesis which is addressed later in this discussion.
An additional subpopulation o f cells lacking the paired domain but possessing
regions encoded by both exons 6 and 10 further supports a role for paired-domain-lacking
isoforms in development. This population had a Pax5 pattern PD-/E6+/E10+ and a B cell
signature PD-/E6+/E10+/HCmu-/Xbpl+/EBF+. Elowever, these cells expressed lower
levels o f X bpl as compared to the earliest developing B cells, suggesting that they have
progressed to a later stage o f B cell development.
The role o f cells lacking the Pax5 paired domain but expressing the Pax5 Cterminus in development was further evidenced by our murine model. Mouse bone
marrow cells displayed similar patterns to the trout anterior kidney cells; the bone
marrow had a population o f cells that lacked the Pax5 paired domain but co-expressed
EBF and the Pax5 C-terminus. As we do not currently have an equivalent antibody for
the exon 6 domain o f murine Pax5, we do not know whether bone marrow cells express
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isoforms with the Pax5 C-terminus solely in progenitor B cells or if earlier developing
cells also express isoforms with the C-terminus. In the anterior kidney, the majority o f
early developing cells expressed both exon 6 and exon 10 o f Pax5, suggesting these two
exons are expressed on similar isoforms.
The anterior kidney represents the primary site of hematopoiesis [3]. However,
our results demonstrated that trout spleen also houses a population o f early developing
cells. Currently, there are no available surface markers, such as CD43 and CD34, to
identify trout hematopoietic cells, but our findings suggest that hematopoiesis occurs in
this secondary immune tissue. While this discovery o f early developing cells in spleen is
the first report of such a population in teleosts, it reflects similar findings in mammals
which have demonstrated human and porcine hematopoiesis occurring in the adult spleen
[101]. Importantly, we show that in both mouse and trout spleen, these early developing
B cells lack the paired domain and express the Pax5 repressor domain (E10), further
supporting a role for Pax5 isoforms lacking the paired domain in development.

4.2 The Pax5 patterns o f late developing B cells
Late developing B cells o f the anterior kidney include the small pre-B, immature,
and mature B cells [32]. These cells have previously been characterized as having high
Pax5 expression, HCmu expression, and low FSC. This trend was further supported by
our data. In the anterior kidney, we consistently observed a population o f cells expressing
paired domain isoforms that were low in FSC (Figure 11). What is interesting about this
population o f developing B cells is that they had higher paired domain expression than
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exon 6 and exon 10 expression. This late developing population is composed of
approximately 20-30% lymphocytes, consistent with previous findings that late
developing cells expressing Pax5 constitute approximately 18.2% o f the anterior kidney
[32]. The higher expression o f the Pax5 paired domain in these late developing cells
suggests there is an upregulation o f isoforms expressing the paired domain (including full
length Pax5) as early as the pre-B stage o f development. An additional subpopulation o f
these late developing cells co-stained all three Pax5 isoforms and presumably expresses
full length Pax5. Although similar patterns are observed in trout and mouse, it should be
noted that we do not observe the same degree o f co-staining in murine bone marrow.
Consistent with earlier studies from our lab [32] one possible explanation for this is that
the trout anterior kidney consists o f more late-developing B cells (18.2%) than murine
bone marrow (13.4%).

4.3 The Pax5 patterns o f activated and differentiating B cells.
A great majority of lymphocytes in the trout spleen (and presumably blood) are
either mature or activated B cells [2, 16]. Such cells co-expressed each o f the three tested
Pax5 domains, suggesting that mature B cells express the full length Pax5. A
subpopulation o f mature B cells upregulated its Pax5 C-terminus expression but not its
paired domain expression. These cells were larger than resting B cells and were possibly
partially activated B cells. This notion is supported by the LPS data, which demonstrates
that, in activated B cells, C-terminus expression per cell is upregulated while the paired
domain expression per cell remains constant. When mature B cells were LPS activated,

84

we observed a relative increase in expression for all three Pax5 domains, suggesting that
the full length isoform is upregulated upon initial activation o f mature B cells. Murine
splenocytes also upregulate Pax5 upon initial activation, as demonstrated by increases in
Pax5 RNA expression [82]. This is the first time a similar trend has been observed for
Pax5 protein in trout using flow cytometry.
The role of the C-terminus in Pax5 function remains largely unknown, with the
exception that it contains an inhibitory domain adjacent to an upstream transactivation
domain [71]. In mice, deletion o f the last 22-33 amino acids o f the C-terminus results in
increased Pax5 transactivating potential, suggesting that the Pax5 transactivation domain
is strongly regulated by the adjacent inhibitory domain [71]. However, the loss o f the Cterminus does not affect the ability o f Groucho family members to repress Pax5
transactivation of target protein [70]. Thus, it is difficult to establish how maintenance o f
the C-terminus (as opposed to the maintenance o f the paired domain) is important for
Pax5 function during LPS activation.
There are several further pieces o f evidence from our lab that B cell activation by
LPS, results in an increase in the frequency o f cells lacking a paired domain. First, using
RT-PCR and primers targeting the full length Pax5 isoform and isoforms lacking exon2
(paired domain) in LPS activated spleen cells, we identified an increase in the ratio o f
paired domain-less isoforms to paired domain containing isoforms across days o f
activation (Bruce and Zwollo, unpublished data). Furthermore, we were able to correlate
this with an increased ratio o f secreted IgM to membrane IgM. Together, these results
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suggest that as cells are activated and differentiate into antibody-secreting plasma cells,
they are expressing more isoforms lacking the paired domain.
In addition to this in vitro approach examining isoform expression, our lab has
also observed in vivo changes in isoform expression using spawning O. nerka samples
(Bruce, Clister, Epp, Schouten, and Zwollo, unpublished results). Spawning fish are
known to have increased immune activation. Using RT-PCR, our lab has observed an
increase in the ratio o f exon 2 lacking isoforms to exon 2 containing isoforms in these
spawning fish relative to non-spawning trout controls. Furthermore, this ratio correlates
with an increased ratio o f secreted to membrane IgM. Together, these findings correlate
with findings o f the present study which demonstrate that during terminal B cell
differentiation, activated B cells will shift towards the paired domain lacking forms o f
Pax5.

4.4 The Pax5 patterns o f peripheral blood.
The peripheral blood is a highly variable and dynamically changing population,
potentially harboring resting, mature B cells while transporting activated and long-lived
plasma cells to their destinations [3, 76]. Our results demonstrate that in addition to
mature and activated B cells, the blood also potentially contains early developing B cells.
These cells lack Pax5 paired domain expression yet still express high levels o f protein
expressing exon 6 (Figure 11). We have not yet tested if this population co-stains the
early B cell marker EBF, but it does exhibit high X bpl expression (Figure 12) and RAG
(an early developmental marker similar to EBF), suggesting it truly represents early
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developing cells (Barr and Zwollo, unpublished). Additionally, the blood also contained a
population of cells that were low in paired domain and exon 6 expression, yet consisting
o f the Pax5 exon 10. It is possible that these cells represent the population o f early
activated B cells described earlier. However, due to the variability in blood, it is difficult
to truly ascertain the identity o f these populations, a point discussed further in the
limitations of this study.

4.5 Pax5 isoform model.
Our initial hypothesis proposed that Pax5 isoform expression modulates the
activity of Pax5 to affect B cell development and activation. We predicted that specific
isoforms would be present in both developing and activated B cell populations and that
the presence or absence o f a particular isoform would either result in the progression or
inhibition o f the B cell developmental pathway (see Chap. 1, Figure 1.6). Although we do
not yet know the function of individual isoforms, we have discovered that particular B
cell stages are characterized by the expression o f specific Pax5 protein domains (Figure
16). Our preliminary model suggested that isoforms containing the Pax5 paired domain
would drive B cell development and that those isoforms lacking the paired domain would
inhibit it. Our current model (Figure 16) supports this prediction; the paired domain is
progressively turned on throughout early B cell development, starting at the pre-B cell
stage, and remains part o f Pax5 until the plasmablast stage. However, isoforms lacking in
paired domain expression, including isoforms containing the repressor domain and exon
6 domain, may already be present at the earliest stages o f B cell development including
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the common lymphocyte progenitor stage. Importantly, in contrast to our original model
(Chap. 1 Figure 1.6), Pax5 isoforms containing the C-terminal repressor domain may be
necessary to promote B cell development rather than inhibit it. This model is supported
by our observation that C-terminal containing isoforms are present during the pro-B cell
stage o f Pax5 (Figure 16).
Our preliminary model further suggested that the C-terminus was necessary for B
cell terminal B cell differentiation and that the absence o f the repressor domain would
inhibit this process. The TPS activation experiments support this hypothesis. The
frequency o f mature and activated cells expressing the C-terminus increased throughout
activation, as did the relative number o f Pax5.E10 positive iso forms per cell. In contrast,
the frequency o f these cells expressing the paired domain decreased and additionally, the
number of isoforms per cell expressing Pax5.PD remained constant. This supports the
prediction that the isoforms lacking the paired domain are necessary for terminal B cell
differentiation, while isoforms containing the repressor domain keep their function even
later in the terminal differentiation process, possibly until the transitional plasma cell
stage.
Our results also suggest that specific Pax5 isoforms may characterize other
possible novel B cell populations, such as phagocytic B cells (Li et al., 2006) or memory
B cells (Ye et al., 2011). In this study, we identified an interesting population o f cells low
in Pax5 paired domain expression, high in Pax5 C-terminus expression, and lacking
HCmu expression. We propose that this population may represent phagocytic B cells
lacking in IgM expression. As the current literature has not examined Pax5 expression in
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phagocytic B cells, this possibility should be addressed in future studies (see later
section).

4.6 Pax5 signatures.
By characterizing the B cell populations o f a tissue through their flow cytometric
patterns o f Pax5 domain expression and delineating the frequencies o f these B cell
populations, we can create a Pax5 signature for each unique immune tissue. The Pax5
signature of a tissue is a means by which researchers can identify aberrant molecular
expression via changes in the frequencies o f key B cell populations. The Pax5 signature
can be used to compare immune tissues across species or to compare different tissues
within a species (i.e. anterior kidney and blood). It can also be used in diagnostics by
comparing the Pax5 signature o f a tissue exposed to pathogen versus a control (as
demonstrated in the next section), or by examining a malignant tissue compared to a
healthy tissue. As research further elucidates the patterns o f Pax5 isoform expression in
developing B cell populations, the more these patterns can be applied to examine immune
tissues as a whole. The ability to apply a Pax5 signature to immune tissues will be
beneficial to both future comparative and clinical immunology studies.
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transitional plasma cell; M. plasma cell: mature plasma cell.
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4.7 Flavobacterium resistant versus susceptible fish.
Bacterial cold water disease (CWBD) is prevalent in aquaculture and is
responsible for high mortality rates in salmonid species [93]. Understanding the
molecular mechanisms underlying fish resistance to this disease will better equip the
aquaculture industry to prevent disease. Our preliminary results demonstrate that
changes in B cell development and the humoral response may contribute to the
mechanisms leading to flavobacterium resistance. Our data showed a higher frequency o f
early developing B cell populations in the anterior kidney and blood o f fish resistant to
CWBD compared to susceptible fish. Although more experiments are required to
determine if these changes are statistically significant, the early developing B cell
population (containing exon 6 o f Pax5) remains an excellent candidate population to
study as it is present in all immune tissues. Additionally, preliminary observations o f this
same population in the anterior kidney o f splenectomized trout demonstrate it is a
dynamic population: there is a lower frequency o f exon 6 expressing B cells in
splenectomized trout anterior kidney compared to control trout (Zwollo, unpublished
data). This suggests that the early developing B cell population responds to atypical
changes in the immune tissues as it needs mature cell to replace those mature B cells lost
from the splenectomy. It supports preliminary evidence that higher frequencies o f early
developing B cell populations may be characteristic o f fish resistant to infection.
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4.8 Limitations to the current study.
The current flow cytometric approach enabled us to demarcate novel B cell
populations in rainbow trout and to demonstrate that these populations differ in their
patterns o f Pax5 domain expression. However, there are populations in the current study
that remain elusive without the availability o f further immunological markers. One such
population is the Pax5 positive populations that lack IgM HCmu expression.
Approximately 15-20% o f gated lymphocytes constituted this population in spleen
(Figure 10) and the population was additionally observed in anterior kidney and blood
(data not shown). This same population has previously been reported by our lab [32, 76].
Recent research has identified the presence o f phagocytic B cells and B -l cells in trout
[102, 103]. However, each o f these studies utilizes IgM as a B cell marker. So far, no
research has examined Pax5 expression in phagocytic B cells. It is possible that our
population o f cells expressing Pax5 but lacking in IgM constitutes some o f the IgM
lacking phagocytic B cells. Alternatively, these cells could represent an early developing
B cell population; however, this is unlikely as these cells did not co-stain for EBF.
Additional experiments to test the phagocytic hypothesis are presented in the next
section.
The flow cytometric patterns o f Pax5 subpopulations were remarkably consistent
across experiments. Although we were able to utilize these patterns to identify individual
B cell populations, it remains formally plausible that observed patterns are not a
reflection o f alternative splicing events. Instead, because multiple regulatory proteins
interact with Pax5 to modify transcription throughout B cell development, it is formally
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possible that protein-protein interactions block available Pax5 sites for antibody binding
in the context o f flow cytometry experiments. .
Although protein-protein interactions may account for our findings, independent
data from Western blots using the three anti-Pax5 antibodies (Figure 2) supports that
alternative splicing is responsible for the observed flow cytometric patterns. Notably,
these blots reveal that anterior kidney contains less o f the paired domain containing
isoforms at the molecular weight for full length Pax5, suggesting that full length Pax5 is
not expressed as frequently in this tissue. Furthermore, the full length Pax5 protein is
found in both trout blood and spleen, consistent with our finding that mature and
activated B cells contain full length Pax5. The blots additionally reveal that the Pax5.E10
antibody recognizes both full length Pax5 and an additional isoform o f smaller molecular
weight in blood and spleen. This matches the high frequency o f a Pax5.E10 population
that lacks the Pax5 paired domain in these tissues. Finally, the blots demonstrate that
Pax5.E6 is found consistently across tissues, thus matching the flow cytometry data.
Western blot analysis reveals the complexity o f Pax5 patterns occurring across
immune tissues and demonstrates that examining protein expression as a collective sum
o f the entire immune tissue protein expression leads to a poor understanding o f Pax5
protein function. Our flow cytometric approach in conjunction with Pax5 antibody
staining remedies this problem by identifying protein expression in individual B cell
populations. Additionally, our approach has revealed multiple, Pax5 containing B cell
populations regardless whether the mechanism resulting in these patterns is a
consequence o f alternative splicing or stage specific protein-protein interactions.
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Therefore, our flow-cytometric technique has promising medical applications when
assessing B cell populations in malignancies such lymphomas and myelomas.
Two-color flow and three-color cytometry is limited in its ability to identify all
Pax5 isoforms. At this time, we have developed an approach to identify which specific
Pax5 domains are present, but we still lack information for the Pax5 domains for which
we do not possess antibodies, including the highly complex exon 7-9 region which
undergoes extensive alternative splicing in humans, mouse, and trout [9, 12]. Therefore,
we are still currently unable to determine if only one isoform is expressed per B cell
population, or if multiple isoforms are expressed within a given population. However,
one key advantage o f our approach is that we may use the current antibodies to detect if
the paired domain, exon 6 and exon 10 regions are absent from a B cell population. Thus,
we are still able to gamer important information on how key Pax5 domains are expressed
and potentially used during B cell development and activation.

4.9 Future studies.
The primary goal o f future studies will be to verify the presence o f Pax5 isoforms
in the populations revealed by flow cytometry. One obvious experiment is to transfect
Pax5 isoforms isolated by RT-PCR into 293T cell lines and demonstrate that the flow
cytometric patterns for these cells are similar to those identified in this study. However,
this approach may not work, as the same caveat o f interfering protein-protein interaction
would persist. An alternative approach would be to separate early developing murine B
cells via cell surface markers (not available for trout) and use RT-PCR to demonstrate
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that isoforms containing the Pax5 C-terminus, but not paired domain, are more prevalent
in these cells than in later developing stages. Although this experiment examines Pax5 at
the RNA level and therefore may accurately demonstrate protein levels, it could still
provide evidence that particular Pax5 isoforms are more present in any particular B cell
developmental stage.
A second goal for future directions is to further characterize the unknown Pax5
expressing, IgM negative population in trout spleen. It has been postulated that this
population is composed o f non-conventional B cell types, such as phagocytic B cells or
B -l cells. One method to test this hypothesis is to culture trout immune cells in the
presence o f fluorescent beads and use two-color flow cytometry to identify if phagocytic
cells are Pax5 positive and IgM negative. If our hypothesis is correct, we would predict
that a subset o f phagocytic B cells is present in trout spleen that are lacking in HCmu but
positive for full length Pax5 expression.

Conclusion.
B cell development and activation are complex, dynamic, and remarkably
conserved processes in vertebrates. The use o f serological reagents and surface markers
in mammalian models has enhanced our understanding o f these processes by enabling us
to demarcate distinct stages o f the developmental pathway. Only recently has research
opened our eyes to the unique implementation o f adaptive immunity in teleosts. We now
know that despite lacking the traditional primary immune organ, the bone marrow,
teleosts follow a developmental pathway comparable to their mammalian counterparts.
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They share similar B cell stages, secondary immune locations, and most importantly,
expression o f Pax5 isoforms.
Using our flow cytometric approach, we have discovered that isoform expression
changes during B cell development and activation stages, and potentially begins at an
earlier stage than previously assumed. By better understanding these complex
developmental pathways, we open future avenues to characterizing immune system
malignancies and furthermore, provide an approach to analyze aberrant molecular
expression. We also pose important evolutionary questions. It is fascinating that teleosts
and mammals share similar early developing B cell populations lacking in Pax5 paired
domain expression and furthermore express these developing B cell populations in
similar secondary immune tissues. How these similarities in Pax5 isoform expression
evolved and where they diverge remain elusive. However, by identifying Pax5 isoforms
in individual developing and activated B cell populations, our research brings us one step
closer to understanding their biological validity and function in humoral immunity.
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